{"gene":"VCAM1","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":1989,"finding":"VCAM-1 was cloned as a novel cytokine-induced endothelial adhesion molecule that binds lymphocytes; it is a member of the immunoglobulin gene superfamily induced by IL-1 or TNF-alpha on human endothelial cells, mediating binding of mononuclear leukocytes but not neutrophils.","method":"Expression cloning by adhesion selection, transfection, mRNA induction assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with functional validation, highly cited foundational study","pmids":["2688898"],"is_preprint":false},{"year":1991,"finding":"The human VCAM1 gene contains 9 exons spanning ~25 kb; alternative splicing of exon 5 produces two VCAM-1 precursors (6-domain and 7-domain forms). The promoter contains functional NF-κB, GATA, and AP1 binding sites.","method":"Genomic cloning, Southern blotting, chromosomal mapping (human-mouse hybrid cell lines and in situ hybridization), mRNA splicing analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct genomic structural analysis with multiple orthogonal methods","pmids":["1715583"],"is_preprint":false},{"year":1991,"finding":"VCAM-1 binds B cell precursors to bone marrow fibroblasts via the integrin VLA-4 (CD49d/CD29); anti-VCAM-1 antibody blocked adhesion of normal B cell precursors, establishing the VLA-4/VCAM-1 axis in B cell precursor retention in bone marrow.","method":"Antibody blocking adhesion assays, flow cytometry, co-culture of B cell precursors with bone marrow fibroblasts","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — reciprocal antibody blocking experiments with primary cells and cell lines","pmids":["1715889"],"is_preprint":false},{"year":1991,"finding":"A seven-domain (long) form of human VCAM-1 was cloned; both six-domain and seven-domain forms support adhesion of VLA-4-expressing cell lines, with the long form being the major form expressed on endothelium.","method":"cDNA cloning, immunoprecipitation with deglycosylation, transfection of COS7 cells, adhesion assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct protein biochemistry with functional validation","pmids":["1707873"],"is_preprint":false},{"year":1992,"finding":"The VCAM-1 promoter is activated by TNF-alpha through two functional NF-κB sites at positions -77 and -63 bp; silencer elements between -1.641 kb and -288 bp restrict constitutive activity; NF-κB responsiveness is cell-type specific (present in endothelial cells but not Jurkat T cells).","method":"Deletion reporter (CAT) constructs transfected into bovine aortic endothelial cells, EMSA (gel retardation assays), TNF-alpha stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — promoter deletion analysis with EMSA, replicated in subsequent studies","pmids":["1379595"],"is_preprint":false},{"year":1992,"finding":"Functional NF-κB and GATA elements in the VCAM-1 core promoter are required for TNF-induced transcription in endothelial cells; new transcription (not mRNA stabilization) drives cytokine-induced VCAM-1 expression.","method":"Deletion reporter constructs, transfection into bovine aortic endothelial cells, nuclear run-on assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — transcriptional run-on assays combined with promoter deletion analysis","pmids":["1281211"],"is_preprint":false},{"year":1993,"finding":"The murine VCAM1 gene has 10 exons spanning ~20 kb; exon 5 encodes a novel domain unique to murine VCAM-1 and inclusion by alternative splicing produces a truncated three-Ig-domain form anchored by a phosphatidylinositol linkage. The murine and human VCAM1 promoters share conserved NF-κB, Ets, and GATA binding sites.","method":"Genomic cloning, exon mapping, sequence analysis, alternative splicing characterization","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 — direct genomic structural characterization","pmids":["7507076"],"is_preprint":false},{"year":1995,"finding":"Genetic ablation of murine Vcam1 causes failure of allantois-chorion fusion at E8.5, resulting in defective placentation and embryonic lethality, revealing an essential developmental role for VCAM-1 in chorioallantoic fusion.","method":"Targeted homologous recombination (knockout mice), embryological analysis, histology","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined developmental phenotype","pmids":["7530222"],"is_preprint":false},{"year":1995,"finding":"Both domain 1 and domain 4 of VCAM-1 independently support VLA-4 (α4β1)-dependent monocyte transendothelial migration; combined blockade of both domains is required for complete inhibition, and their relative contribution depends on the duration of endothelial IL-1 activation.","method":"Domain-specific anti-VCAM-1 mAb blocking assays, CHO cell transfection with 6-domain and 7-domain VCAM-1 constructs, monocyte migration assays under C5a gradient","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — domain-specific antibody blockade combined with transfected cell systems","pmids":["7545712"],"is_preprint":false},{"year":1995,"finding":"Membrane-bound VCAM-1 is converted to a soluble 100-kDa form by regulated metalloprotease-dependent proteolytic cleavage; EDTA and 1,10-phenanthroline (metalloprotease inhibitors) block this conversion, and phorbol ester induces shedding with concurrent loss of membrane-bound form.","method":"Biochemical characterization, metalloprotease inhibitor treatment, phorbol ester stimulation, immunoprecipitation of intracellular precursors and soluble forms in T cell clones","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — pharmacological inhibitor experiments identifying metalloprotease-dependent shedding mechanism","pmids":["7529789"],"is_preprint":false},{"year":1997,"finding":"TNF-alpha activates p38 MAP kinase in endothelial cells; p38 inhibition (SB203580) suppresses TNF-alpha-induced surface expression of VCAM-1 but not ICAM-1, without affecting VCAM-1 mRNA accumulation, indicating p38 regulates VCAM-1 at the post-transcriptional level.","method":"p38 MAPK inhibitor (SB203580), MAPKAP kinase 2 activity assays, Hsp27 phosphorylation, flow cytometry for surface expression, Northern blot for mRNA","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — orthogonal methods (kinase activity, protein expression, mRNA) in single study","pmids":["9020057"],"is_preprint":false},{"year":1999,"finding":"α9β1 integrin on neutrophils binds VCAM-1 and mediates stable adhesion and transendothelial neutrophil migration; α9β1 is highly expressed on neutrophils and contributes to chemotaxis across activated endothelium alongside α4 integrins.","method":"Cell adhesion assays with recombinant VCAM-1, antibody blocking of α9β1, transendothelial migration assays with TNF-alpha-activated HUVEC","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal adhesion and migration assays identifying novel integrin-VCAM-1 interaction","pmids":["10209034"],"is_preprint":false},{"year":1999,"finding":"PPARα activators (fenofibrate, WY14643) inhibit TNF-alpha-induced VCAM-1 mRNA expression in human endothelial cells, in part by inhibiting NF-κB activation, and reduce monocyte adhesion; this identifies PPARα as a transcriptional regulator of VCAM-1.","method":"RT-PCR, transfection with VCAM-1 promoter deletion constructs, EMSA, monocyte adhesion assays, immunohistochemistry","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — promoter analysis + EMSA + functional adhesion assays in multiple systems","pmids":["10377075"],"is_preprint":false},{"year":2000,"finding":"VCAM-1 on fibroblast-like synoviocytes (FLS) interacts with CD49d/CD29 (VLA-4) on B cells to rescue synovial B cells from apoptosis and upregulate Bcl-xL expression in a contact-dependent manner; anti-VCAM-1 antibody blocked both effects.","method":"Co-culture of synovial fluid B cells with FLS, antibody blocking, viability assays (trypan blue, annexin V, Hoechst staining), Western blot for Bcl-xL","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blocking with multiple viability readouts in a single study","pmids":["10817566"],"is_preprint":false},{"year":2000,"finding":"RA synovial stromal cell VCAM-1 (CD106) interaction with CD49d/CD29 (VLA-4) on B cells induces Bcl-xL upregulation and protects B cells from apoptosis in a contact-dependent manner; anti-CD106 but not anti-CD54 antibody blocked these effects.","method":"Co-culture with stromal cell lines, antibody blocking, flow cytometry, Bcl-xL/Bcl-2 Western blot","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal blocking antibody experiments with defined molecular readout","pmids":["10623863"],"is_preprint":false},{"year":2001,"finding":"VCAM-1 expressed by bone marrow stromal cells is proteolytically cleaved by neutrophil serine proteases (neutrophil elastase and cathepsin G) during G-CSF-induced hematopoietic progenitor cell mobilization, enabling HSC egress.","method":"In vivo mouse mobilization model, immunohistochemistry, in vitro protease cleavage assays with recombinant VCAM-1 and purified neutrophil elastase/cathepsin G","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of protease cleavage combined with in vivo genetic evidence","pmids":["11520773"],"is_preprint":false},{"year":2002,"finding":"VCAM-1 interacts directly with moesin and ezrin (ERM proteins) and colocalizes with them at the apical endothelial surface. During leukocyte adhesion, VCAM-1, ICAM-1, activated moesin and ezrin cluster in an endothelial actin-rich docking structure that partially embraces the adherent leukocyte; this structure requires phosphoinositides and the Rho/ROCK pathway.","method":"In vitro direct binding assay (GST pulldown), live-cell imaging, immunofluorescence, siRNA-mediated knockdown, pharmacological inhibition of Rho/ROCK, dynamic fluorescence microscopy under flow","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — direct binding reconstituted in vitro + live imaging with functional validation","pmids":["12082081"],"is_preprint":false},{"year":2003,"finding":"PMA-stimulated shedding of VCAM-1 from the cell surface is mediated specifically by TACE (ADAM17), a metalloproteinase that cleaves VCAM-1 near the transmembrane domain to produce soluble VCAM-1; cells from ADAM17-deficient mice lack PMA-induced VCAM-1 shedding.","method":"Metalloproteinase inhibitors, ADAM17-deficient mouse-derived cells, VCAM-1 shedding assays, comparison with E-selectin/PECAM-1/ICAM-1 shedding","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic KO cells identifying specific protease, replicated with inhibitor pharmacology","pmids":["12878595"],"is_preprint":false},{"year":2006,"finding":"Lymphocyte binding to VCAM-1 activates endothelial cell NADPH oxidase, generating ~1 μM H2O2, which in turn induces oxidation and activation of PKCα (phosphorylation at Thr638); this PKCα activation is required for VCAM-1-dependent leukocyte transendothelial migration.","method":"Dominant-negative PKCα overexpression, PKCα inhibitors (Rö-32-0432, Gö-6976), H2O2 scavenging, NADPH oxidase inhibition, anti-VCAM-1 antibody cross-linking, PKCα oxidation assay, spleen cell migration under laminar flow","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal pharmacological and dominant-negative approaches converging on same mechanism","pmids":["17056569"],"is_preprint":false},{"year":2008,"finding":"miR-126 is expressed by endothelial cells and inhibits VCAM-1 expression; reduction of miR-126 increases TNF-alpha-stimulated VCAM-1 expression and enhances leukocyte adherence, while overexpression of miR-126 precursor decreases VCAM-1 levels.","method":"Transfection of endothelial cells with miR-126 inhibitor or precursor oligonucleotides, VCAM-1 protein/mRNA quantification, leukocyte adhesion assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — bidirectional manipulation (gain and loss of function) with two orthogonal readouts","pmids":["18227515"],"is_preprint":false},{"year":2011,"finding":"VCAM-1 aberrantly expressed on breast cancer cells tethers macrophages via α4-integrins; clustering of cancer cell surface VCAM-1, acting through Ezrin, activates PI3K/Akt signaling and protects cancer cells from TRAIL-induced apoptosis in leukocyte-rich microenvironments such as the lung.","method":"Co-culture of breast cancer cells with macrophages, antibody blocking of α4-integrins, dominant-negative Ezrin, Akt activation assays, TRAIL apoptosis assay, in vivo lung metastasis mouse model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — mechanistic epistasis with dominant-negative constructs + in vivo validation","pmids":["22014578"],"is_preprint":false},{"year":2011,"finding":"Aberrant VCAM-1 expression on breast cancer micrometastases in bone promotes transition from dormancy to overt metastasis by recruiting α4β1-positive monocytic osteoclast progenitors via VCAM-1/α4β1 interaction, elevating local osteoclast activity; anti-VCAM-1 and anti-α4 antibodies inhibit this process.","method":"Bone metastasis dormancy mouse model, NF-κB pathway manipulation, VCAM-1 overexpression, antibody blockade, osteoclast activity assays, in vivo imaging","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — genetic manipulation + antibody blockade + in vivo model with mechanistic readout","pmids":["22137794"],"is_preprint":false},{"year":2012,"finding":"IRF-1 and miR-126 reciprocally regulate VCAM-1 expression in response to triglyceride-rich lipoproteins (TGRL): proatherogenic TGRL increase IRF-1 and decrease miR-126, inducing VCAM-1; antiatherogenic TGRL do the opposite. Overexpression or silencing of IRF-1 or miR-126 recapitulates these effects.","method":"HAEC transfection with IRF-1 overexpression/silencing and miR-126 overexpression/silencing, VCAM-1 expression assay, monocyte arrest assay","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional manipulation of two regulators with functional monocyte arrest readout","pmids":["22874466"],"is_preprint":false},{"year":2012,"finding":"Nuclear-localized FAK (kinase-inhibited) binds GATA4 transcription factor via its FERM domain, promoting CHIP E3 ligase-dependent polyubiquitination and degradation of GATA4; loss of GATA4 reduces VCAM-1 expression. Active FAK facilitates TNF-α-induced MAPK activation and GATA4 stability, thereby supporting VCAM-1 expression.","method":"Pharmacological FAK inhibition, conditional endothelial FAK knockout mice, nuclear fractionation, direct FAK-GATA4 binding assay, CHIP co-immunoprecipitation, GATA4 ubiquitination assay, in vivo heart vessel analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — direct binding, ubiquitination assay, genetic KO and pharmacological inhibition with in vivo validation","pmids":["22734001"],"is_preprint":false},{"year":2013,"finding":"Metastatic tumor cell attachment induces endothelial VCAM-1 (dependent on tumor cell-clot/tissue factor formation); endothelial VCAM-1 recruits myeloid cells that support tumor cell survival and metastasis; VCAM-1 blocking antibody reduces myeloid recruitment and diminishes metastasis without affecting tumor cell adhesion.","method":"In vivo pulmonary metastasis mouse model, VCAM-1 blocking antibody, tissue factor pathway inhibitor/hirudin treatment, flow cytometry for myeloid cells, tumor cell survival assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blockade with mechanistic upstream pathway identification in vivo","pmids":["23407548"],"is_preprint":false},{"year":2014,"finding":"VLA-4 (α4β1) on leukocytes interacts with VCAM-1 to mediate reciprocal NF-κB activation in both leukemia cells and bone marrow mesenchymal stromal cells; this bidirectional signaling promotes stromal-mediated chemoresistance, reversible by VLA-4/VCAM-1 blockade or NF-κB inhibition.","method":"Genome-wide gene expression profiling of BM-MSCs, co-culture, NF-κB reporter assays, mutant IκBα overexpression, VLA-4 blocking antibody, in vivo human leukemia BM microenvironment model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic (dominant-negative) and pharmacological blockade with in vivo validation","pmids":["24599548"],"is_preprint":false},{"year":2015,"finding":"Tumor-derived SPARC induces endothelial vascular permeability and cancer cell extravasation through VCAM-1 and p38 MAPK signaling; blocking VCAM-1 impedes SPARC-induced permeability and extravasation.","method":"Comparative proteomic analysis of melanoma secretomes, SPARC knockdown/overexpression, VCAM-1 blocking antibody, vascular permeability assays, lung metastasis mouse model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — genetic manipulation of SPARC and antibody blockade of VCAM-1 with in vivo validation","pmids":["25925867"],"is_preprint":false},{"year":2015,"finding":"VCAM-1 is a TGF-β1-inducible gene in lung fibroblasts (via transcriptional induction, not mRNA stabilization); VCAM-1 depletion inhibits fibroblast proliferation, causing G2/M and S phase arrest associated with reduced phospho-ERK1/2 and cyclin D1.","method":"TGF-β1 treatment, VCAM-1 siRNA depletion, mRNA stability assays, cell cycle analysis, Western blot for phospho-ERK1/2 and cyclin D1","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with cell cycle and signaling readouts","pmids":["26386411"],"is_preprint":false},{"year":2016,"finding":"oxLDL induces NF-κB activation and VCAM-1 expression through FAK-dependent activation of RSK (p90 ribosomal S6 kinase), which activates IKKβ; transgenic mice with endothelial-specific kinase-dead FAK show reduced RSK activity, decreased VCAM-1 expression, and reduced macrophage accumulation in atherosclerotic regions.","method":"RSK inhibitors, FAK kinase-dead transgenic mice, IKKβ activation assays, NF-κB reporter, monocyte adhesion assay, atherosclerosis model","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — pharmacological + genetic (kinase-dead transgene) with in vivo atherosclerosis validation","pmids":["26906414"],"is_preprint":false},{"year":2017,"finding":"VCAM-1 expression in glioblastoma depends on EGFR expression, and is regulated via the p38/STAT3 signaling pathway; miR-181b, via protein phosphatase 2A-modulated SP-1 dephosphorylation, controls EGFR-dependent VCAM-1 expression and thereby monocyte adhesion to GBM cells through integrin α4β1.","method":"EGFR inhibition, VCAM-1 knockdown, integrin α4β1 blocking, miR-181b overexpression/inhibition, PP2A assay, SP-1 phosphorylation Western blot, 2D/3D co-culture adhesion assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple signaling components manipulated with functional adhesion readout","pmids":["28459461"],"is_preprint":false},{"year":2017,"finding":"VCAM-1 signals through its intracellular domain to regulate β-catenin signaling in embryonic radial glial cells (RGCs) in a context-dependent manner; loss of VCAM-1 in RGCs stimulates premature neuronal differentiation and prevents quiescence, depleting the embryonic origin of postnatal neural stem cells.","method":"Conditional Vcam1 knockout mice (region- and stage-specific), β-catenin reporter assays, BrdU labeling, clonal analysis, in vitro neural stem cell assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic KO with defined cellular phenotype and molecular pathway (β-catenin) identified","pmids":["28728023"],"is_preprint":false},{"year":2017,"finding":"VCAM-1 synergizes with Delta-like 4 (DLL4) to enhance Notch signaling in hematopoietic stem and progenitor cells and promote T-lineage differentiation; VCAM-1 additionally activates an inflammatory transcriptional program in nascent HSPCs.","method":"Defined stromal cell-free in vitro T cell differentiation system, DLL4/VCAM-1 protein presentation on surfaces, Notch reporter assays, flow cytometry for T cell progenitors, in vivo thymus colonization","journal":"Nature methods","confidence":"Medium","confidence_rationale":"Tier 2 — reconstituted defined niche system with Notch signaling readout","pmids":["28394335"],"is_preprint":false},{"year":2018,"finding":"VCAM-1+ macrophage-like 'usher' cells patrol the inner surface of the venous plexus in zebrafish caudal haematopoietic tissue, interact with HSPCs via ITGA4, and direct HSPC retention at vascular homing hotspots.","method":"Advanced live imaging in zebrafish, cell-labelling system, ITGA4 blocking, in vivo loss-of-function","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — high-resolution live imaging with molecular (ITGA4) blocking in vivo","pmids":["30455424"],"is_preprint":false},{"year":2019,"finding":"Brain endothelial VCAM-1 mediates the detrimental effects of aged plasma on young brains: aged plasma elevates VCAM-1 on BECs; anti-VCAM-1 antibody administration or genetic ablation of Vcam1 in BECs counteracts microglial reactivity and cognitive deficits induced by aged plasma in young mice.","method":"Systemic anti-VCAM-1 antibody, conditional endothelial Vcam1 KO mice, parabiosis/plasma transfer model, microglial activation assays, cognitive behavioral tests","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO and antibody blockade with in vivo functional (cognitive) readout","pmids":["31086348"],"is_preprint":false},{"year":2021,"finding":"M2 macrophage VLA-4 (α4β1) engagement with endothelial VCAM-1 induces vascular permeability through a RAC1/ROS/PYK2 phosphorylation/VE-cadherin phosphorylation cascade; downregulation of VLA-4 or VCAM-1 reduces RAC1 and ROS, decreases p-PYK2 and p-VE-cadherin, and enhances barrier integrity. Targeting the VLA-4/VCAM-1 axis abrogates ascites formation in vivo.","method":"VLA-4 overexpression/knockdown, VCAM-1 overexpression in ECs, RAC1/ROS/PYK2/VE-cadherin signaling assays, vascular permeability assay, in vivo ovarian cancer ascites model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — defined molecular cascade with multiple orthogonal perturbations and in vivo validation","pmids":["33295887"],"is_preprint":false},{"year":2021,"finding":"HDAC1/2 promote endothelial VCAM-1 expression by suppressing STAT3 acetylation-dependent methylation (via DNMT1) of the GATA6 promoter; HDAC1/2 inhibition increases STAT3 acetylation, promotes STAT3-DNMT1 interaction, leads to GATA6 promoter hypermethylation, reduces GATA6 and VCAM-1 expression, and attenuates atherosclerosis.","method":"HDAC1/2 siRNA, Romidepsin treatment, methylation-specific PCR, ChIP for STAT3 at GATA6 promoter, STAT3 Lys685Arg acetylation-blocking mutant, DNMT1 co-immunoprecipitation, ApoE-/- mouse atherosclerosis model","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 — mechanistic epistasis with mutant constructs, ChIP, and in vivo validation","pmids":["33859766"],"is_preprint":false},{"year":2022,"finding":"VCAM-1 on haematopoietic stem cells serves as a 'don't-eat-me' signal providing innate immune tolerance; this function is regulated by β2-microglobulin/MHC-I presentation on HSCs and paired Ig-like receptor-B (PIR-B) on phagocytes. VCAM-1 deletion in haplotype-mismatched settings impairs HSC engraftment due to phagocytic clearance.","method":"Vcam1 conditional KO, haplotype-mismatch transplantation, MHC-I/β2m blocking, PIR-B KO phagocytes, phagocytosis assays, in vivo HSC engraftment assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple mechanistic components (MHC-I, PIR-B) and in vivo engraftment readout","pmids":["35210567"],"is_preprint":false},{"year":2022,"finding":"DLL4 and VCAM-1 synergize to activate Notch signaling in nascent HSPCs during endothelial-to-haematopoietic transition, enhancing T cell progenitor output ~80-fold; VCAM-1 additionally promotes an inflammatory transcriptional program in HSPCs.","method":"Defined serum/feeder-free PSC differentiation system, single-protein presentation, Notch reporter, transcriptomic analysis, flow cytometry, in vivo T cell maturation","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — defined reconstituted system with Notch signaling and transcriptomic readouts","pmids":["36001668"],"is_preprint":false},{"year":2023,"finding":"IL-33 induces VCAM-1 in microglia, which promotes microglial chemotaxis toward amyloid-β plaques by sensing plaque-associated ApoE; disrupting the VCAM-1-ApoE interaction abolishes microglial Aβ chemotaxis and decreases Aβ clearance.","method":"IL-33 stimulation of microglia, VCAM-1 functional screening, VCAM-1-ApoE interaction blocking, Aβ chemotaxis assays, in vivo Alzheimer's disease mouse model","journal":"Nature aging","confidence":"Medium","confidence_rationale":"Tier 2 — functional screening identifying VCAM-1 as chemotactic receptor for ApoE, blocking validates specificity","pmids":["37735240"],"is_preprint":false},{"year":2021,"finding":"Membrane-bound SCF and VCAM-1 synergistically regulate HSC morphology: HSCs cluster membrane-bound SCF at the HSC-bilayer interface and form a polarized morphology with large protrusion; VCAM-1 dramatically enhances HSC adhesion to the bilayer through a mechanism requiring PI3K signaling and cytoskeletal reorganization, and the synergy enhances nuclear retention of FOXO3a.","method":"Supported lipid bilayer reconstitution system, PI3K inhibitors, cytoskeletal disruption, FOXO3a localization by immunofluorescence, HSC adhesion force measurements","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 1 — reconstituted bilayer system with PI3K epistasis and defined morphological/signaling readout","pmids":["34402812"],"is_preprint":false},{"year":2015,"finding":"Notch1 intracellular domain (N1ICD) in endothelial cells upregulates Jagged1 and directly induces VCAM-1 expression in the absence of inflammatory cytokines; Notch1/Jagged1 circuit amplifies IL-1β-induced VCAM-1 induction. γ-Secretase inhibition and Notch1/Jagged1 silencing abrogate IL-1β-mediated VCAM-1 induction.","method":"γ-Secretase inhibitor, Notch1/Jagged1 siRNA silencing, forced N1ICD expression, VCAM-1 quantification, in vivo chronic liver inflammation model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional Notch1 manipulation with VCAM-1 as direct transcriptional target readout","pmids":["26646450"],"is_preprint":false},{"year":2020,"finding":"H. pylori infection increases VCAM-1 expression in cancer-associated fibroblasts via JAK/STAT1 signaling; CAF-derived VCAM-1 physically interacts with integrin αvβ1/5 on gastric cancer cells to facilitate tumor invasion in vitro and in vivo.","method":"RNA-seq of H. pylori-infected fibroblasts, JAK/STAT1 inhibitors, biolayer interferometry for VCAM1-integrin binding kinetics, zebrafish xenograft invasion model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding kinetics assay (BLI) + genetic manipulation + in vivo xenograft model","pmids":["32034307"],"is_preprint":false},{"year":2024,"finding":"H3K18 lactylation in the gastric cancer tumor microenvironment transcriptionally activates VCAM-1; VCAM-1 in turn activates AKT-mTOR signaling to promote GC cell proliferation and migration, and upregulates CXCL1 via AKT-mTOR to recruit mesenchymal stem cells and M2 macrophages.","method":"H3K18 lactylation ChIP, VCAM-1 overexpression/knockdown, AKT-mTOR pathway inhibitors, CXCL1 quantification, macrophage/MSC recruitment assays, GC mouse models","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — epigenetic ChIP combined with pathway inhibition and recruitment functional assays","pmids":["38461905"],"is_preprint":false},{"year":2024,"finding":"Proinflammatory cytokines (TNF-α and IL-1β) induce NF-κB-dependent VCAM-1 expression in proximal tubule cells; tubular VCAM-1 overexpression or TNF-α stimulation increases splenocyte adhesion to tubular monolayers; pharmacological NF-κB inhibition or genetic Vcam1 deletion suppresses this tubule-immune cell adhesion.","method":"TNF-α/IL-1β treatment of immortalized mouse proximal tubular cells and primary renal cells, NF-κB inhibitors, MyD88/TRIF double-KO cells, VCAM-1 overexpression, splenocyte adhesion assay, single-cell transcriptomics of patient biopsies","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO and overexpression with functional adhesion readout in multiple cell systems","pmids":["39116349"],"is_preprint":false},{"year":2022,"finding":"VCAM-1-bearing endothelial cell-derived extracellular vesicles (EVs) are rapidly released after myocardial infarction and accumulate in the spleen, where they induce inflammatory gene expression and mobilize splenic neutrophils to peripheral blood; CRISPR/Cas9 deletion of VCAM-1 in endothelial cells removes the ability of EVs to provoke neutrophil mobilization.","method":"CRISPR/Cas9 VCAM-1-deficient endothelial cells, EV characterization (size/marker), in vivo splenic neutrophil mobilization assay, miRNA-126 in vivo inhibition, MI mouse model","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR genetic deletion in EV-producing cells with in vivo functional readout","pmids":["35134856"],"is_preprint":false}],"current_model":"VCAM-1 is a cytokine-inducible, NF-κB/GATA-regulated immunoglobulin superfamily transmembrane glycoprotein on endothelial and other cells that mediates leukocyte, HSPC, and cancer cell adhesion primarily through VLA-4 (α4β1) and α9β1 integrins; its extracellular domain is shed as a soluble form by ADAM17/TACE and neutrophil serine proteases; its cytoplasmic tail signals through NADPH oxidase-generated H2O2, PKCα oxidation, Ezrin/moesin-dependent actin docking structures, and β-catenin pathways; additional upstream regulators include p38 MAPK (post-transcriptional), FAK-GATA4 (nuclear ubiquitination), HDAC1/2-STAT3-GATA6 (epigenetic), miR-126, and Notch1-Jagged1, collectively positioning VCAM-1 as a multi-context adhesion and signaling hub in inflammation, hematopoiesis, development, neurodegeneration, and cancer metastasis."},"narrative":{"teleology":[{"year":1989,"claim":"Identification of VCAM-1 as a new cytokine-inducible endothelial adhesion molecule for lymphocytes established it as a member of the immunoglobulin superfamily mediating selective leukocyte recruitment.","evidence":"Expression cloning by adhesion selection from IL-1/TNF-α–stimulated HUVEC cDNA library","pmids":["2688898"],"confidence":"High","gaps":["Ligand on the leukocyte side not yet identified","In vivo function unknown","Signaling capacity of the cytoplasmic tail uncharacterized"]},{"year":1991,"claim":"Genomic characterization revealed alternative splicing producing 6- and 7-domain isoforms, and identification of NF-κB/GATA/AP1 promoter elements explained cytokine-inducible transcription, while the VLA-4 (α4β1) integrin was identified as the counter-receptor mediating B cell precursor retention in bone marrow.","evidence":"Genomic cloning, promoter-reporter analysis, EMSA, antibody-blocking adhesion assays with bone marrow fibroblasts and B cell precursors","pmids":["1715583","1707873","1715889"],"confidence":"High","gaps":["Relative functional contribution of 6- vs 7-domain isoforms in vivo unclear","Other integrin counter-receptors not yet explored","Mechanism of NF-κB cell-type specificity not resolved"]},{"year":1992,"claim":"Detailed promoter dissection confirmed that tandem NF-κB sites and a GATA element are essential for TNF-α–induced transcription, ruling out mRNA stabilization as the primary induction mechanism.","evidence":"Deletion reporter constructs, nuclear run-on assays, EMSA in bovine aortic endothelial cells","pmids":["1379595","1281211"],"confidence":"High","gaps":["Identity of the GATA family member driving endothelial expression unknown","Chromatin-level regulation not addressed"]},{"year":1995,"claim":"Three key mechanistic advances: (1) Vcam1 knockout mice revealed embryonic lethality from failed chorioallantoic fusion, establishing a non-immune developmental role; (2) domains 1 and 4 were shown to independently mediate VLA-4–dependent monocyte transmigration; (3) regulated metalloprotease-dependent ectodomain shedding was identified as a mechanism generating soluble VCAM-1.","evidence":"Targeted gene disruption in mice; domain-specific mAb blocking in transmigration assays; metalloprotease inhibitor studies with immunoprecipitation","pmids":["7530222","7545712","7529789"],"confidence":"High","gaps":["Identity of the sheddase not yet determined","Whether placentation failure reflects adhesion vs signaling function unknown","Physiological role of soluble VCAM-1 undefined"]},{"year":1997,"claim":"Discovery that p38 MAPK selectively controls VCAM-1 surface expression post-transcriptionally (without affecting mRNA levels) revealed a layer of regulation beyond NF-κB–driven transcription.","evidence":"p38 inhibitor SB203580 in TNF-α–stimulated endothelial cells with parallel mRNA and surface protein quantification","pmids":["9020057"],"confidence":"Medium","gaps":["Post-transcriptional mechanism (translation, trafficking, or stability) not specified","Only pharmacological inhibitor used, no genetic confirmation"]},{"year":1999,"claim":"Identification of α9β1 as a second integrin counter-receptor on neutrophils expanded VCAM-1's adhesion repertoire beyond VLA-4, explaining neutrophil interaction that was initially thought absent.","evidence":"Recombinant VCAM-1 adhesion assays and α9β1 antibody blocking in transendothelial migration","pmids":["10209034"],"confidence":"High","gaps":["Relative contribution of α9β1 vs α4β1 in vivo not delineated","Structural basis of dual-integrin recognition unknown"]},{"year":2002,"claim":"Direct interaction of VCAM-1 with ezrin and moesin was demonstrated, and live imaging revealed VCAM-1/ICAM-1/ERM actin-rich docking structures that embrace adherent leukocytes, establishing a cytoskeletal signaling function for VCAM-1's cytoplasmic tail.","evidence":"GST pulldown for direct binding, live-cell dynamic fluorescence microscopy under flow, pharmacological inhibition of Rho/ROCK","pmids":["12082081"],"confidence":"High","gaps":["Specific cytoplasmic tail residues mediating ERM binding not mapped","Whether docking structures are required for transmigration vs firm adhesion not resolved"]},{"year":2003,"claim":"ADAM17 (TACE) was identified as the specific metalloproteinase responsible for PMA-stimulated VCAM-1 ectodomain shedding, resolving the identity of the sheddase.","evidence":"ADAM17-deficient mouse-derived cells lack PMA-induced VCAM-1 shedding; metalloproteinase inhibitor pharmacology","pmids":["12878595"],"confidence":"High","gaps":["Cleavage site not precisely mapped","Whether ADAM17 mediates constitutive shedding or only stimulated shedding unclear"]},{"year":2006,"claim":"Leukocyte binding to VCAM-1 was shown to activate endothelial NADPH oxidase, generating H₂O₂ that oxidizes and activates PKCα, which is required for transendothelial migration—linking VCAM-1 engagement to a reactive oxygen species signaling cascade.","evidence":"Dominant-negative PKCα, PKCα inhibitors, NADPH oxidase inhibition, anti-VCAM-1 cross-linking in endothelial cells under laminar flow","pmids":["17056569"],"confidence":"High","gaps":["How VCAM-1 cytoplasmic tail couples to NADPH oxidase activation not defined","Whether PKCα oxidation is the sole downstream effector unknown"]},{"year":2008,"claim":"miR-126 was established as a post-transcriptional negative regulator of VCAM-1 in endothelial cells, with bidirectional gain- and loss-of-function demonstrating its role in tuning leukocyte adhesion.","evidence":"Transfection of miR-126 inhibitor/precursor in endothelial cells with VCAM-1 protein/mRNA quantification and leukocyte adhesion assay","pmids":["18227515"],"confidence":"High","gaps":["Whether miR-126 directly targets VCAM-1 3ʹ UTR or acts indirectly not fully resolved","In vivo significance in inflammation not tested"]},{"year":2011,"claim":"VCAM-1 was repurposed in cancer: aberrant expression on breast cancer cells tethers macrophages via α4-integrins, activating Ezrin–PI3K/Akt pro-survival signaling in cancer cells; separately, VCAM-1 on bone micrometastases recruits osteoclast progenitors to switch dormancy to overt metastasis.","evidence":"Dominant-negative Ezrin, α4 blocking, TRAIL apoptosis and Akt assays, bone metastasis dormancy mouse models","pmids":["22014578","22137794"],"confidence":"High","gaps":["Whether VCAM-1–Ezrin–Akt axis operates in non-breast cancers untested","Mechanism of VCAM-1 transcriptional reactivation in cancer cells not defined"]},{"year":2012,"claim":"Upstream regulatory complexity expanded: FAK–GATA4 nuclear pathway controls VCAM-1 via CHIP-mediated GATA4 ubiquitination, and IRF-1/miR-126 reciprocal regulation links lipid metabolism to VCAM-1 in atherogenesis.","evidence":"Conditional endothelial FAK KO, direct FAK–GATA4 binding, CHIP co-IP and ubiquitination assay; IRF-1/miR-126 bidirectional manipulation with monocyte arrest readout","pmids":["22734001","22874466"],"confidence":"High","gaps":["Whether GATA4 or GATA6 predominates in different vascular beds unclear","FAK–GATA4 mechanism not tested outside cardiac endothelium"]},{"year":2015,"claim":"Notch1 intracellular domain was shown to directly induce VCAM-1 in the absence of inflammatory cytokines, adding a developmental signaling pathway to VCAM-1 regulation; concurrently, tumor-derived SPARC was found to induce endothelial VCAM-1 via p38 MAPK to promote cancer cell extravasation.","evidence":"Forced N1ICD expression, γ-secretase inhibition, Notch1/Jagged1 siRNA; SPARC manipulation with VCAM-1 blocking in melanoma lung metastasis model","pmids":["26646450","25925867"],"confidence":"Medium","gaps":["Whether Notch1 binds the VCAM-1 promoter directly or acts through intermediaries not shown","Generalizability of SPARC–VCAM-1 axis across tumor types unknown"]},{"year":2017,"claim":"VCAM-1's intracellular signaling was shown to regulate β-catenin in embryonic radial glial cells, maintaining neural stem cell quiescence; separately, VCAM-1 synergized with DLL4 to enhance Notch signaling in HSPCs for T-lineage differentiation.","evidence":"Conditional Vcam1 KO in embryonic brain, β-catenin reporter, BrdU labeling; defined stromal-free DLL4/VCAM-1 co-presentation system with Notch reporter","pmids":["28728023","28394335"],"confidence":"High","gaps":["How VCAM-1 cytoplasmic domain activates β-catenin mechanistically unknown","Whether VCAM-1 directly potentiates Notch receptor activation or acts through co-signaling unclear"]},{"year":2019,"claim":"Brain endothelial VCAM-1 was identified as a mediator of aging-associated neuroinflammation: aged plasma elevates brain endothelial VCAM-1, and genetic ablation or antibody blockade reverses microglial reactivity and cognitive decline in young mice receiving aged plasma.","evidence":"Conditional endothelial Vcam1 KO, anti-VCAM-1 antibody, parabiosis/plasma transfer, cognitive behavioral tests","pmids":["31086348"],"confidence":"High","gaps":["Factor(s) in aged plasma responsible for VCAM-1 induction not identified","Whether VCAM-1 signals to microglia directly or recruits peripheral immune cells not resolved"]},{"year":2021,"claim":"Two new signaling cascades were delineated: (1) macrophage VLA-4/endothelial VCAM-1 engagement activates RAC1/ROS/PYK2/VE-cadherin phosphorylation to induce vascular permeability; (2) VCAM-1 with membrane-bound SCF on lipid bilayers synergistically promotes HSC adhesion, polarized morphology, and FOXO3a nuclear retention via PI3K.","evidence":"VLA-4/VCAM-1 overexpression/knockdown with vascular permeability assays and in vivo ascites model; reconstituted supported lipid bilayer with PI3K inhibitors and FOXO3a imaging","pmids":["33295887","34402812"],"confidence":"High","gaps":["Whether PYK2 is a direct substrate of VCAM-1 outside-in signaling unknown","HSC bilayer findings not yet validated in bone marrow niche in vivo"]},{"year":2021,"claim":"An epigenetic circuit was uncovered: HDAC1/2 sustain VCAM-1 expression by preventing STAT3 acetylation-driven DNMT1 recruitment and GATA6 promoter methylation, linking chromatin remodeling to VCAM-1 transcriptional control in atherosclerosis.","evidence":"HDAC1/2 siRNA, romidepsin, STAT3 acetylation-blocking mutant, methylation-specific PCR, ChIP, ApoE⁻/⁻ mouse atherosclerosis model","pmids":["33859766"],"confidence":"High","gaps":["Relative importance of GATA4 vs GATA6 in different endothelial beds unresolved","Whether HDAC3 has compensatory roles not tested"]},{"year":2022,"claim":"VCAM-1 on HSCs was revealed as a 'don't-eat-me' signal conferring innate immune tolerance, regulated by β2-microglobulin/MHC-I and recognized by PIR-B on phagocytes; additionally, VCAM-1–bearing endothelial extracellular vesicles were found to mobilize splenic neutrophils after myocardial infarction.","evidence":"Conditional Vcam1 KO in haplotype-mismatch transplantation, PIR-B KO phagocytes, phagocytosis assays; CRISPR/Cas9 VCAM-1 deletion in endothelial EV-producing cells with in vivo neutrophil mobilization","pmids":["35210567","35134856"],"confidence":"High","gaps":["Whether VCAM-1 don't-eat-me function operates through direct PIR-B binding or via MHC-I co-presentation not distinguished","VCAM-1 EV cargo composition and receptor on splenic neutrophils undefined"]},{"year":2023,"claim":"A non-canonical role emerged: IL-33–induced microglial VCAM-1 senses plaque-associated ApoE to direct microglial chemotaxis toward amyloid-β plaques, establishing VCAM-1 as a chemotactic receptor in neurodegeneration.","evidence":"VCAM-1–ApoE interaction blocking, Aβ chemotaxis assays, Alzheimer's disease mouse model","pmids":["37735240"],"confidence":"Medium","gaps":["VCAM-1–ApoE binding interface not structurally defined","Whether this represents a direct receptor–ligand interaction or requires co-receptors unknown","Relevance to human AD not established"]},{"year":2024,"claim":"Epigenetic and metabolic regulation of VCAM-1 was extended: H3K18 lactylation activates VCAM-1 transcription in gastric cancer, where VCAM-1 drives AKT–mTOR signaling and CXCL1-mediated immune cell recruitment; NF-κB–dependent tubular VCAM-1 was shown to mediate immune cell adhesion in kidney inflammation.","evidence":"H3K18 lactylation ChIP with VCAM-1 overexpression/knockdown and AKT–mTOR inhibitors; TNF-α/IL-1β treatment of tubular cells with NF-κB inhibition and Vcam1 genetic deletion","pmids":["38461905","39116349"],"confidence":"Medium","gaps":["Whether lactylation-driven VCAM-1 induction is tumor-type specific unknown","Tubular VCAM-1 findings limited to in vitro models"]},{"year":null,"claim":"Key unresolved questions include: how the VCAM-1 cytoplasmic tail couples to NADPH oxidase and β-catenin signaling; the structural basis for dual-integrin (α4β1/α9β1) and ApoE recognition; whether the 'don't-eat-me' function operates through direct PIR-B engagement; and the in vivo functional significance of the distinct 6- and 7-domain isoforms.","evidence":"","pmids":[],"confidence":"High","gaps":["Cytoplasmic tail signaling adaptor identity unknown","No high-resolution structure of full-length VCAM-1 with integrin or ApoE","Isoform-specific functions not tested in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,2,3,8,11,16,20,21]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[20,30,36]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[18,30,38]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,8,9,16,17,33]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[9,15,17,44]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[44]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,8,11,18,33,36]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,8,16,20,21,34]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,18,25,30,34,42]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,30,31,37]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,21,29,41,42]}],"complexes":[],"partners":["ITGA4","ITGA9","EZR","MSN","ADAM17","CTNNB1","DLL4","APOE"],"other_free_text":[]},"mechanistic_narrative":"VCAM-1 is a cytokine-inducible immunoglobulin superfamily transmembrane glycoprotein that serves as a central adhesion and signaling hub on endothelial, stromal, and other cell types, mediating leukocyte, hematopoietic stem cell, and cancer cell interactions through binding VLA-4 (α4β1) and α9β1 integrins [PMID:2688898, PMID:10209034]. Its transcription is driven by NF-κB and GATA elements in the proximal promoter and is further regulated by Notch1/Jagged1 signaling, HDAC1/2–STAT3–GATA6 epigenetic circuits, miR-126, and FAK–GATA4 nuclear ubiquitination pathways [PMID:1379595, PMID:18227515, PMID:33859766, PMID:22734001, PMID:26646450]. Engagement of VCAM-1 by integrin-bearing leukocytes activates endothelial NADPH oxidase–derived H₂O₂, PKCα oxidation, and Ezrin/moesin-dependent actin docking structures that facilitate transendothelial migration, while its extracellular domain is proteolytically shed by ADAM17 and neutrophil serine proteases to modulate adhesion in inflammation and hematopoietic progenitor mobilization [PMID:17056569, PMID:12082081, PMID:12878595, PMID:11520773]. Beyond classical leukocyte trafficking, VCAM-1 regulates embryonic chorioallantoic fusion, neural stem cell quiescence via β-catenin signaling, HSC immune tolerance as a 'don't-eat-me' signal, brain endothelial aging-associated neuroinflammation, and cancer cell survival and metastasis through PI3K/Akt and AKT–mTOR pathways [PMID:7530222, PMID:28728023, PMID:35210567, PMID:31086348, PMID:22014578]."},"prefetch_data":{"uniprot":{"accession":"P19320","full_name":"Vascular cell adhesion protein 1","aliases":["INCAM-100"],"length_aa":739,"mass_kda":81.3,"function":"Cell adhesion glycoprotein predominantly expressed on the surface of endothelial cells that plays an important role in immune surveillance and inflammation (PubMed:31310649). Acts as a major regulator of leukocyte adhesion to the endothelium through interaction with different types of integrins (PubMed:10209034). During inflammatory responses, binds ligands on the surface of activated endothelial cells to initiate the activation of calcium channels and the plasma membrane-associated small GTPase RAC1 leading to leukocyte transendothelial migration (PubMed:22970700). Also serves as a quality-control checkpoint for entry into bone marrow by providing a 'don't-eat-me' stamping in the context of major histocompatibility complex (MHC) class-I presentation (PubMed:35210567)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P19320/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VCAM1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/VCAM1","total_profiled":1310},"omim":[{"mim_id":"620579","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 3; CCDC3","url":"https://www.omim.org/entry/620579"},{"mim_id":"619642","title":"TRANSMEMBRANE p24 TRAFFICKING PROTEIN 2; TMED2","url":"https://www.omim.org/entry/619642"},{"mim_id":"617462","title":"PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA, COACTIVATOR-RELATED PROTEIN 1; PPRC1","url":"https://www.omim.org/entry/617462"},{"mim_id":"611767","title":"MICRO RNA 126; MIR126","url":"https://www.omim.org/entry/611767"},{"mim_id":"608272","title":"NEURAMINIDASE 1; NEU1","url":"https://www.omim.org/entry/608272"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cell Junctions","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":366.8}],"url":"https://www.proteinatlas.org/search/VCAM1"},"hgnc":{"alias_symbol":["CD106"],"prev_symbol":[]},"alphafold":{"accession":"P19320","domains":[{"cath_id":"2.60.40.10","chopping":"27-114","consensus_level":"high","plddt":90.7343,"start":27,"end":114},{"cath_id":"2.60.40.10","chopping":"121-218","consensus_level":"medium","plddt":87.4664,"start":121,"end":218},{"cath_id":"2.60.40.10","chopping":"222-310","consensus_level":"medium","plddt":91.0194,"start":222,"end":310},{"cath_id":"2.60.40.10","chopping":"315-402","consensus_level":"medium","plddt":90.4103,"start":315,"end":402},{"cath_id":"2.60.40.10","chopping":"409-506","consensus_level":"medium","plddt":85.5996,"start":409,"end":506},{"cath_id":"2.60.40.10","chopping":"510-598","consensus_level":"medium","plddt":91.2902,"start":510,"end":598},{"cath_id":"2.60.40.10","chopping":"604-687","consensus_level":"high","plddt":86.6483,"start":604,"end":687}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19320","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19320-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19320-F1-predicted_aligned_error_v6.png","plddt_mean":84.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VCAM1","jax_strain_url":"https://www.jax.org/strain/search?query=VCAM1"},"sequence":{"accession":"P19320","fasta_url":"https://rest.uniprot.org/uniprotkb/P19320.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19320/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19320"}},"corpus_meta":[{"pmid":"31086348","id":"PMC_31086348","title":"Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31086348","citation_count":339,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7530222","id":"PMC_7530222","title":"Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation.","date":"1995","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7530222","citation_count":309,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37442359","id":"PMC_37442359","title":"ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders.","date":"2023","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37442359","citation_count":275,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7689792","id":"PMC_7689792","title":"Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation.","date":"1993","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7689792","citation_count":211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9020057","id":"PMC_9020057","title":"p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9020057","citation_count":177,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25925867","id":"PMC_25925867","title":"Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25925867","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22461363","id":"PMC_22461363","title":"Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22461363","citation_count":154,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11786095","id":"PMC_11786095","title":"AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11786095","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1707873","id":"PMC_1707873","title":"Cloning of an alternate form of vascular cell adhesion molecule-1 (VCAM1).","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1707873","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30455424","id":"PMC_30455424","title":"VCAM-1+ macrophages guide the homing of HSPCs to a vascular niche.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30455424","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8808648","id":"PMC_8808648","title":"Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis.","date":"1996","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/8808648","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28394335","id":"PMC_28394335","title":"Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1.","date":"2017","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/28394335","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22874466","id":"PMC_22874466","title":"IRF-1 and miRNA126 modulate VCAM-1 expression in response to a high-fat meal.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22874466","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38461905","id":"PMC_38461905","title":"H3K18 lactylation-mediated VCAM1 expression promotes gastric cancer progression and metastasis via AKT-mTOR-CXCL1 axis.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38461905","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22734001","id":"PMC_22734001","title":"Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression.","date":"2012","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22734001","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12121861","id":"PMC_12121861","title":"ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation.","date":"2002","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12121861","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23285079","id":"PMC_23285079","title":"Adiponectin and leptin induce VCAM-1 expression in human and murine chondrocytes.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23285079","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24721610","id":"PMC_24721610","title":"Mobilization with granulocyte colony-stimulating factor blocks medullar erythropoiesis by depleting F4/80(+)VCAM1(+)CD169(+)ER-HR3(+)Ly6G(+) erythroid island macrophages in the mouse.","date":"2014","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24721610","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10623863","id":"PMC_10623863","title":"Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10623863","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23407548","id":"PMC_23407548","title":"VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23407548","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16734619","id":"PMC_16734619","title":"Cytokines differentially regulate ICAM-1 and VCAM-1 expression on human gingival fibroblasts.","date":"2006","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16734619","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18600396","id":"PMC_18600396","title":"Changes in the expression of CD106, osteogenic genes, and transcription factors involved in the osteogenic differentiation of human bone marrow mesenchymal stem cells.","date":"2008","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18600396","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26386411","id":"PMC_26386411","title":"VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26386411","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32034307","id":"PMC_32034307","title":"Cancer-associated fibroblasts-derived VCAM1 induced by H. pylori infection facilitates tumor invasion in gastric cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32034307","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28459461","id":"PMC_28459461","title":"MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28459461","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7529789","id":"PMC_7529789","title":"Expression of VCAM-1 (CD106) by a subset of TCR gamma delta-bearing lymphocyte clones. Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7529789","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10817566","id":"PMC_10817566","title":"Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes.","date":"2000","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/10817566","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26906414","id":"PMC_26906414","title":"Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1 expression.","date":"2016","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26906414","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17056569","id":"PMC_17056569","title":"VCAM-1 signals activate endothelial cell protein kinase Calpha via oxidation.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17056569","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29187895","id":"PMC_29187895","title":"Follicular Stimulating Hormone Accelerates Atherogenesis by Increasing Endothelial VCAM-1 Expression.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/29187895","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33295887","id":"PMC_33295887","title":"Macrophage-mediated vascular permeability via VLA4/VCAM1 pathway dictates ascites development in ovarian cancer.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33295887","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7543623","id":"PMC_7543623","title":"ICAM-1 and VCAM-1 in human renal allograft rejection.","date":"1995","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/7543623","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24968096","id":"PMC_24968096","title":"SIRPA, VCAM1 and CD34 identify discrete lineages during early human cardiovascular development.","date":"2014","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24968096","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28728023","id":"PMC_28728023","title":"Persistent Expression of VCAM1 in Radial Glial Cells Is Required for the Embryonic Origin of Postnatal Neural Stem Cells.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28728023","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8649201","id":"PMC_8649201","title":"Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells.","date":"1996","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/8649201","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10335877","id":"PMC_10335877","title":"Estimation of wound age and VCAM-1 in human skin.","date":"1999","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10335877","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35134856","id":"PMC_35134856","title":"Rapid neutrophil mobilization by VCAM-1+ endothelial cell-derived extracellular vesicles.","date":"2023","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/35134856","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34058204","id":"PMC_34058204","title":"Regulatory effects of IL-1β in the interaction of GBM and tumor-associated monocyte through VCAM-1 and ICAM-1.","date":"2021","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34058204","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29325582","id":"PMC_29325582","title":"Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.","date":"2018","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29325582","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28500253","id":"PMC_28500253","title":"LINC00341 exerts an anti-inflammatory effect on endothelial cells by repressing VCAM1.","date":"2017","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/28500253","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33138124","id":"PMC_33138124","title":"VCAM-1 Target in Non-Invasive Imaging for the Detection of Atherosclerotic Plaques.","date":"2020","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33138124","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33859766","id":"PMC_33859766","title":"HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33859766","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37735240","id":"PMC_37735240","title":"The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer's disease pathology.","date":"2023","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/37735240","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30338362","id":"PMC_30338362","title":"Purinergic receptor Y2 (P2Y2)- dependent VCAM-1 expression promotes immune cell infiltration in metabolic syndrome.","date":"2018","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30338362","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37118362","id":"PMC_37118362","title":"Mendelian randomization of genetically independent aging phenotypes identifies LPA and VCAM1 as biological targets for human aging.","date":"2022","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/37118362","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20720203","id":"PMC_20720203","title":"P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil accumulation during lung inflammation.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20720203","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19597294","id":"PMC_19597294","title":"Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms.","date":"2009","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/19597294","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18951693","id":"PMC_18951693","title":"Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18951693","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31186752","id":"PMC_31186752","title":"Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31186752","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10678623","id":"PMC_10678623","title":"Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts.","date":"2000","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/10678623","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7545712","id":"PMC_7545712","title":"Domains 1 and 4 of vascular cell adhesion molecule-1 (CD106) both support very late activation antigen-4 (CD49d/CD29)-dependent monocyte transendothelial migration.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7545712","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24803492","id":"PMC_24803492","title":"Involvement of VCAM1 in the bovine conceptus adhesion to the uterine endometrium.","date":"2014","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24803492","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7680963","id":"PMC_7680963","title":"Regulation of VCAM-1 expression and involvement in cell adhesion to murine microvascular endothelium.","date":"1993","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7680963","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8640376","id":"PMC_8640376","title":"A direct binding assay for the vascular cell adhesion molecule-1 (VCAM1) interaction with alpha 4 integrins.","date":"1995","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/8640376","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21034812","id":"PMC_21034812","title":"3,3'-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via a BRCA1-dependent antioxidant pathway.","date":"2010","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21034812","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30496704","id":"PMC_30496704","title":"Endothelial NOD1 directs myeloid cell recruitment in atherosclerosis through VCAM-1.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30496704","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29222072","id":"PMC_29222072","title":"Heparan sulfate potentiates leukocyte adhesion on cardiac fibroblast by enhancing Vcam-1 and Icam-1 expression.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29222072","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33087490","id":"PMC_33087490","title":"Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism.","date":"2020","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/33087490","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36001668","id":"PMC_36001668","title":"DLL4 and VCAM1 enhance the emergence of T cell-competent hematopoietic progenitors from human pluripotent stem cells.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36001668","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26824050","id":"PMC_26824050","title":"Clopidogrel Protects Endothelium by Hindering TNFα-Induced VCAM-1 Expression through CaMKKβ/AMPK/Nrf2 Pathway.","date":"2015","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/26824050","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28235946","id":"PMC_28235946","title":"VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.","date":"2017","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28235946","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35210567","id":"PMC_35210567","title":"VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35210567","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36453131","id":"PMC_36453131","title":"IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36453131","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35222039","id":"PMC_35222039","title":"Blocking VCAM-1 Prevents Angiotensin II-Induced Hypertension and Vascular Remodeling in Mice.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35222039","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8774481","id":"PMC_8774481","title":"Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma.","date":"1996","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8774481","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25640159","id":"PMC_25640159","title":"PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25640159","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7507076","id":"PMC_7507076","title":"Structure of the murine VCAM1 gene.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7507076","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12713595","id":"PMC_12713595","title":"Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12713595","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11907429","id":"PMC_11907429","title":"Rolling adhesion of human NK cells to porcine endothelial cells mainly relies on CD49d-CD106 interactions.","date":"2002","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/11907429","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11115088","id":"PMC_11115088","title":"Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11115088","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30951142","id":"PMC_30951142","title":"VCAM1 Is Induced in Ovarian Theca and Stromal Cells in a Mouse Model of Androgen Excess.","date":"2019","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30951142","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32936824","id":"PMC_32936824","title":"Human cardiac fibroblasts expressing VCAM1 improve heart function in postinfarct heart failure rat models by stimulating lymphangiogenesis.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32936824","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11684832","id":"PMC_11684832","title":"Expression of PDGF-A, TGFb and VCAM-1 during the developmental stages of experimental atherosclerosis.","date":"2001","source":"European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes","url":"https://pubmed.ncbi.nlm.nih.gov/11684832","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27206739","id":"PMC_27206739","title":"Glycated LDL increase VCAM-1 expression and secretion in endothelial cells and promote monocyte adhesion through mechanisms involving endoplasmic reticulum stress.","date":"2016","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27206739","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33720049","id":"PMC_33720049","title":"VCAM-1: closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33720049","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20220769","id":"PMC_20220769","title":"Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease.","date":"2010","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20220769","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36497180","id":"PMC_36497180","title":"Ectopic Tumor VCAM-1 Expression in Cancer Metastasis and Therapy Resistance.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36497180","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24075742","id":"PMC_24075742","title":"Increased monocyte adhesion by endothelial expression of VCAM-1 missense variation in vitro.","date":"2013","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/24075742","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28441665","id":"PMC_28441665","title":"MicroRNA-1185 Promotes Arterial Stiffness though Modulating VCAM-1 and E-Selectin Expression.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28441665","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36965158","id":"PMC_36965158","title":"Human serum-derived exosomes modulate macrophage inflammation to promote VCAM1-mediated angiogenesis and bone regeneration.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36965158","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26646450","id":"PMC_26646450","title":"Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1β.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26646450","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35743247","id":"PMC_35743247","title":"IL-17 Facilitates VCAM-1 Production and Monocyte Adhesion in Osteoarthritis Synovial Fibroblasts by Suppressing miR-5701 Synthesis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35743247","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15784173","id":"PMC_15784173","title":"Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis.","date":"2005","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15784173","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11817523","id":"PMC_11817523","title":"Soluble VCAM-1 is a very early marker of endothelial cell activation in cardiopulmonary bypass.","date":"2002","source":"Perfusion","url":"https://pubmed.ncbi.nlm.nih.gov/11817523","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11944890","id":"PMC_11944890","title":"Phytochemical inhibition of interleukin-4-activated Stat6 and expression of VCAM-1.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11944890","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11849381","id":"PMC_11849381","title":"Signal transduction of beta2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11849381","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34402812","id":"PMC_34402812","title":"Membrane-bound SCF and VCAM-1 synergistically regulate the morphology of hematopoietic stem cells.","date":"2021","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34402812","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21071353","id":"PMC_21071353","title":"MCP-1, ICAM-1 and VCAM-1 are present in early aneurysmal dilatation in experimental rats.","date":"2010","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/21071353","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26108418","id":"PMC_26108418","title":"Interaction Between Gastric Carcinoma Cells and Neural Cells Promotes Perineural Invasion by a Pathway Involving VCAM1.","date":"2015","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26108418","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12729843","id":"PMC_12729843","title":"Dexamethasone reduces lung eosinophilia, and VCAM-1 and ICAM-1 expression induced by Sephadex beads in rats.","date":"2003","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12729843","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36685605","id":"PMC_36685605","title":"Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer's disease.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36685605","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21073443","id":"PMC_21073443","title":"High-cell density-induced VCAM1 expression inhibits the migratory ability of mesenchymal stem cells.","date":"2011","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/21073443","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39116349","id":"PMC_39116349","title":"VCAM-1 mediates proximal tubule-immune cell cross talk in failed tubule recovery during AKI-to-CKD transition.","date":"2024","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/39116349","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35256782","id":"PMC_35256782","title":"Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35256782","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27123929","id":"PMC_27123929","title":"Th1-Induced CD106 Expression Mediates Leukocytes Adhesion on Synovial Fibroblasts from Juvenile Idiopathic Arthritis Patients.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27123929","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37487253","id":"PMC_37487253","title":"Compound Kushen Injection inhibits epithelial-mesenchymal transition of gastric carcinoma by regulating VCAM1 induced by the TNF signaling pathway.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37487253","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33188835","id":"PMC_33188835","title":"IGFBP-3 stimulates human osteosarcoma cell migration by upregulating VCAM-1 expression.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33188835","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25868755","id":"PMC_25868755","title":"Up-regulation of VCAM1 Relates to Neuronal Apoptosis After Intracerebral Hemorrhage in Adult Rats.","date":"2015","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/25868755","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35256780","id":"PMC_35256780","title":"Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35256780","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12213703","id":"PMC_12213703","title":"Novel expression of vascular cell adhesion molecule-1 (CD106) by squamous epithelium in experimental acute graft-versus-host disease.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12213703","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21833088","id":"PMC_21833088","title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21833088","citation_count":2101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2688898","id":"PMC_2688898","title":"Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2688898","citation_count":1667,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18227515","id":"PMC_18227515","title":"MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18227515","citation_count":857,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10377075","id":"PMC_10377075","title":"PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10377075","citation_count":497,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22014578","id":"PMC_22014578","title":"Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22014578","citation_count":484,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12082081","id":"PMC_12082081","title":"Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes.","date":"2002","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12082081","citation_count":453,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22137794","id":"PMC_22137794","title":"VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22137794","citation_count":413,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23463506","id":"PMC_23463506","title":"The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23463506","citation_count":413,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1281211","id":"PMC_1281211","title":"Functional analysis of the human vascular cell adhesion molecule 1 promoter.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1281211","citation_count":404,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1379595","id":"PMC_1379595","title":"Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1).","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1379595","citation_count":388,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11520773","id":"PMC_11520773","title":"Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11520773","citation_count":373,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9184636","id":"PMC_9184636","title":"Selective expression of adhesion molecules on human brain microvascular endothelial cells.","date":"1997","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/9184636","citation_count":337,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9572733","id":"PMC_9572733","title":"Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9572733","citation_count":320,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17116732","id":"PMC_17116732","title":"An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17116732","citation_count":289,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24599548","id":"PMC_24599548","title":"Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24599548","citation_count":245,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12878595","id":"PMC_12878595","title":"Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17).","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12878595","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10209034","id":"PMC_10209034","title":"The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10209034","citation_count":230,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1715889","id":"PMC_1715889","title":"Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells.","date":"1991","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/1715889","citation_count":227,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19738201","id":"PMC_19738201","title":"Proteomic analysis of integrin-associated complexes identifies RCC2 as a dual regulator of Rac1 and Arf6.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19738201","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11078691","id":"PMC_11078691","title":"beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.","date":"2000","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11078691","citation_count":193,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1715583","id":"PMC_1715583","title":"Gene structure, chromosomal location, and basis for alternative mRNA splicing of the human VCAM1 gene.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1715583","citation_count":191,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53022,"output_tokens":8913,"usd":0.14638},"stage2":{"model":"claude-opus-4-6","input_tokens":12988,"output_tokens":4082,"usd":0.250485},"total_usd":0.901529,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66063,"output_tokens":10879,"usd":0.180687},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":15342,"output_tokens":5571,"usd":0.323977}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"VCAM1 exists in two alternatively spliced isoforms: a 6-domain (short) and a 7-domain (long) form, with the long form being the predominant isoform found on endothelium. Both forms support adhesion of VLA-4 (α4β1 integrin)-expressing cell lines.\",\n      \"method\": \"cDNA cloning, transient transfection of COS7 cells, immunoprecipitation after deglycosylation, cell adhesion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in transfected cells with direct adhesion assay and biochemical characterization\",\n      \"pmids\": [\"1707873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The murine VCAM1 gene spans ~20 kb with 10 exons. Each immunoglobulin-like domain is encoded by a separate exon. Alternative splicing of exon 5 produces a truncated 3-domain isoform anchored by a phosphatidylinositol linkage. The promoter contains conserved NF-κB, Ets, and GATA transcription factor binding sites shared with the human gene.\",\n      \"method\": \"Genomic cloning, sequencing, exon mapping, promoter sequence analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct gene structure determination by sequencing\",\n      \"pmids\": [\"7507076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"VCAM-1 expression on murine microvascular endothelium is upregulated by TNF, IL-1, and LPS (but not PMA or staurosporine), and VCAM-1/VLA-4 interaction mediates adhesion of splenocytes, thymocytes, mast cells, and eosinophils to cytokine-activated endothelium. TGF-β inhibits endothelial adhesiveness without substantially affecting VCAM-1 surface expression.\",\n      \"method\": \"Flow cytometry, monoclonal antibody blocking, rosette-based adhesion assay\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal antibody blocking of VCAM-1 and VLA-4 with multiple cell types\",\n      \"pmids\": [\"7680963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Genetic ablation of murine VCAM1 causes failure of allantois-to-chorion fusion at embryonic day 8.5, leading to defective placentation and embryonic lethality, establishing an essential developmental role for VCAM-1 in chorioallantoic fusion.\",\n      \"method\": \"Targeted homologous recombination (gene knockout), embryo histology\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — genetic loss-of-function with specific developmental phenotype\",\n      \"pmids\": [\"7530222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Both domain 1 and domain 4 of the 7-domain VCAM-1 form can independently support VLA-4 (α4β1)-dependent monocyte transendothelial migration; combined blockade of both domains completely abolishes CD18-independent migration.\",\n      \"method\": \"Transendothelial migration assay across CHO cells transfected with VCAM-6D or VCAM-7D, domain-specific monoclonal antibody blockade\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted migration across transfected monolayers with domain-specific antibody dissection\",\n      \"pmids\": [\"7545712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The membrane-bound form of VCAM-1 (CD106) is converted to a soluble 100 kDa form by proteolytic cleavage involving a zinc-dependent metalloprotease; EDTA and 1,10-phenanthroline (metalloprotease inhibitors) block this conversion, while phorbol ester increases shedding.\",\n      \"method\": \"Biochemical characterization, metalloprotease inhibitor treatment, phorbol ester stimulation, supernatant analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic dissection of shedding with specific inhibitors identifying enzyme class\",\n      \"pmids\": [\"7529789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"VCAM-1 directly binds α4 integrins (VLA-4/α4β1); the α4β1 receptor exists in different affinity states, with high-affinity state induced by manganese ions or activating anti-β1 monoclonal antibodies.\",\n      \"method\": \"Direct binding assay using alkaline phosphatase-coupled VCAM-Ig fusion protein in microtiter plate format, flow cytometry\",\n      \"journal\": \"Cell adhesion and communication\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding reconstitution assay with recombinant proteins\",\n      \"pmids\": [\"8640376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TNF-α activates the p38 MAP kinase signaling cascade in endothelial cells; p38 regulates VCAM-1 surface expression at the post-transcriptional level (the specific p38 inhibitor SB203580 suppresses VCAM-1 surface expression but does not affect VCAM-1 mRNA accumulation).\",\n      \"method\": \"p38 kinase inhibitor (SB203580) treatment, MAPKAP kinase 2 activity assay, Hsp27 phosphorylation, VCAM-1 surface ELISA, Northern blot for mRNA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with orthogonal mRNA and protein readouts\",\n      \"pmids\": [\"9020057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"VCAM-1 (CD106) on rheumatoid arthritis synovial stromal cells rescues B cells from apoptosis and upregulates Bcl-xL expression in a contact-dependent manner via VLA-4 (CD49d/CD29) on B cells; anti-CD106 antibody blocks both survival and Bcl-xL induction.\",\n      \"method\": \"Co-culture of B cells with stromal cell lines, antibody blockade of CD106/CD49d/CD29, apoptosis assays (annexin V, Hoechst), Western blot for Bcl-xL\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal antibody blockade with specific molecular (Bcl-xL) and viability readouts\",\n      \"pmids\": [\"10623863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"VCAM-1 cross-linking activates endothelial cell NADPH oxidase, generating ~1 μM H₂O₂, which in turn induces oxidation and activation of PKCα (at Thr638); this PKCα activation is required for VCAM-1-dependent lymphocyte transendothelial migration.\",\n      \"method\": \"VCAM-1 antibody cross-linking, NADPH oxidase inhibition, H₂O₂ scavenging, dominant-negative PKCα, PKCα inhibitors (Rö-32-0432, Gö-6976), phosphorylation assay, transendothelial migration under laminar flow\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic cascade established with multiple orthogonal inhibitors and dominant-negative approach\",\n      \"pmids\": [\"17056569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"AGEs bind RAGE on mesothelial cells to stimulate VCAM-1 expression (not ICAM-1); anti-RAGE antibodies or recombinant RAGE block this VCAM-1 upregulation, and recombinant VCAM-1 prevents CML-albumin-induced leukocyte adhesion to mesothelial cells.\",\n      \"method\": \"RAGE detection by FACS and RT-PCR, radiometric VCAM-1 expression assay, antibody blockade, leukocyte adhesion by videomicroscopy\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking + functional adhesion readout in single study\",\n      \"pmids\": [\"11786095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Nuclear-localized FAK (kinase-inhibited) binds the FERM domain directly to GATA4 transcription factor and promotes GATA4 polyubiquitination via CHIP E3 ligase, leading to GATA4 degradation and suppression of TNF-α-induced VCAM-1 expression. Pharmacological or genetic FAK inhibition prevents TNF-α-induced VCAM-1 expression in vivo and during development.\",\n      \"method\": \"FAK inhibitor treatment in vivo and in vitro, genetic FAK ablation, co-immunoprecipitation of FAK-FERM with GATA4, CHIP E3 ligase dependence, ubiquitination assay, immunofluorescence for nuclear FAK localization\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct protein interaction (Co-IP), in vitro ubiquitination, nuclear localization imaging, in vivo genetic validation\",\n      \"pmids\": [\"22734001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IRF-1 and miR-126 reciprocally regulate VCAM-1 expression in human aortic endothelial cells in response to triglyceride-rich lipoproteins; overexpression of IRF-1 increases and silencing of IRF-1 decreases VCAM-1, while miR-126 activity suppresses VCAM-1 expression.\",\n      \"method\": \"IRF-1 overexpression/silencing, miR-126 manipulation, VCAM-1 mRNA/protein measurement, monocyte arrest assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function for both regulators with functional monocyte adhesion readout\",\n      \"pmids\": [\"22874466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LINC00341 lncRNA, induced by atheroprotective shear flow, suppresses VCAM-1 expression by recruiting EZH2 (polycomb repressive complex 2 histone methyltransferase) to the VCAM-1 promoter, thereby repressing transcription and reducing monocyte adhesion.\",\n      \"method\": \"RNA-Seq, LINC00341 overexpression, ChIP for EZH2 at VCAM-1 promoter, monocyte adhesion assay\",\n      \"journal\": \"Physiological genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating epigenetic writer recruitment to VCAM-1 promoter with functional adhesion readout\",\n      \"pmids\": [\"28500253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tumor-derived SPARC induces vascular permeability and cancer cell extravasation through endothelial VCAM1 receptor and p38 MAPK signaling; blocking VCAM1 impedes melanoma-induced endothelial permeability and extravasation.\",\n      \"method\": \"SPARC KO/overexpression, VCAM1 blockade, vascular permeability assays, extravasation assay, p38 MAPK pathway inhibition, comparative proteomics of secretomes\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — SPARC KO/OE with VCAM1 blockade and multiple functional readouts\",\n      \"pmids\": [\"25925867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VCAM-1 is a TGF-β1-inducible gene in lung fibroblasts; depletion of VCAM-1 inhibits fibroblast proliferation and causes G2/M and S phase cell cycle arrest associated with reduced phospho-ERK1/2 and cyclin D1 levels.\",\n      \"method\": \"TGF-β1 treatment, VCAM-1 siRNA knockdown, cell cycle analysis, Western blot for p-ERK1/2 and cyclin D1, mRNA stability assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with specific cell-cycle and signaling readouts, single lab\",\n      \"pmids\": [\"26386411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VHL loss or hypoxia in clear cell renal cell carcinoma decreases VCAM-1 expression through NF-κB signaling (independent of HIF); VHL re-expression restores high VCAM-1 levels, which promote anti-tumor immunity through interaction with α4β1 integrin on immune cells.\",\n      \"method\": \"VHL expression/knockdown in ccRCC lines, NF-κB pathway inhibition, VCAM-1 protein/mRNA measurement, immune cell adhesion assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function of VHL with pathway dissection, single lab\",\n      \"pmids\": [\"28235946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Oxidized LDL drives VCAM-1 expression through FAK-dependent activation of RSK, which then activates IKKβ and NF-κB; transgenic mice with endothelial kinase-dead FAK show reduced RSK activity, decreased VCAM-1 expression, and reduced macrophage accumulation in early atherosclerosis.\",\n      \"method\": \"RSK inhibition, FAK kinase-dead transgenic mice, IKKβ/NF-κB activation assays, VCAM-1 expression, monocyte adhesion assay, in vivo atherosclerosis model\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro pathway dissection plus in vivo genetic validation with multiple orthogonal readouts\",\n      \"pmids\": [\"26906414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VCAM-1 signals through its intracellular domain to regulate β-catenin signaling in radial glial cells; loss of VCAM1 stimulates premature neuronal differentiation and prevents quiescence in slowly dividing RGCs, diminishing the embryonic origin of postnatal neural stem cells.\",\n      \"method\": \"Conditional VCAM1 genetic ablation in mice, BrdU/EdU labeling, neurosphere assay, immunofluorescence, domain deletion constructs, β-catenin reporter assay\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO plus intracellular domain functional dissection with multiple stem cell readouts\",\n      \"pmids\": [\"28728023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Synergistic interaction between VCAM-1 and Delta-like 4 (DLL4) enhances Notch signaling in hematopoietic stem and progenitor cells to promote progenitor T-cell differentiation; VCAM-1 additionally promotes an inflammatory transcriptional program in nascent HSPCs.\",\n      \"method\": \"Engineered stromal-cell-free niche with defined protein combinations, T-cell differentiation assay, in vivo thymus colonization, Notch reporter, transcriptional profiling\",\n      \"journal\": \"Nature methods\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — fully defined reconstituted system with genetic readouts and in vivo validation\",\n      \"pmids\": [\"28394335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VCAM-1+ macrophage-like 'usher' niche cells patrol the venous plexus in zebrafish caudal haematopoietic tissue, interact with HSPCs through ITGA4 (integrin α4), and direct HSPC retention in homing microenvironments.\",\n      \"method\": \"High-resolution live imaging in zebrafish, cell labeling, ITGA4 blockade, VCAM-1 expression characterization\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live imaging plus specific ligand-receptor (VCAM1-ITGA4) blockade in ortholog model (zebrafish)\",\n      \"pmids\": [\"30455424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"P2Y2 purinergic receptor signaling regulates both membrane-bound and soluble forms of VCAM-1 on lung endothelial cells; P2Y2 deficiency abolishes UTP-induced VCAM-1 upregulation and reduces eosinophil accumulation in allergic lung inflammation.\",\n      \"method\": \"P2Y2 knockout mice, OVA sensitization model, VCAM-1 expression on lung endothelium by flow cytometry, leukocyte adhesion assay, BAL eosinophil counts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific VCAM-1 and cellular (eosinophil) functional readouts\",\n      \"pmids\": [\"20720203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Brain endothelial VCAM1 at the blood-brain barrier mediates the pro-aging effects of aged blood plasma; systemic anti-VCAM1 antibody or BEC-specific Vcam1 genetic ablation reverses microglial reactivity and cognitive deficits in aged mice and counteracts effects of aged plasma on young brains.\",\n      \"method\": \"BEC-specific Vcam1 conditional knockout, anti-VCAM1 antibody administration, young/aged heterochronic plasma transfer, microglial activation assays, cognitive behavioral tests\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic BEC-specific KO plus antibody intervention with mechanistic and behavioral readouts, replicated\",\n      \"pmids\": [\"31086348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"M2 macrophage-derived VLA4 downregulates VCAM1 on endothelial cells, which reduces RAC1 and ROS levels, decreases phosphorylation of PYK2 and VE-cadherin, and enhances endothelial barrier function; VLA4/VCAM1 overexpression induces hyperpermeability, and targeting this axis abrogates ascites formation in ovarian cancer in vivo.\",\n      \"method\": \"Co-culture of macrophages with endothelium, VLA4/VCAM1 overexpression, RAC1/ROS measurement, p-PYK2/p-VE-cadherin Western blot, in vivo ascites model, VLA4 blocking antibody\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic cascade (VCAM1→RAC1→ROS→PYK2→VE-cad) with gain/loss of function in vitro and in vivo validation\",\n      \"pmids\": [\"33295887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HDAC1/2 promote VCAM-1 expression by suppressing STAT3 acetylation; acetylated STAT3 binds DNMT1 and directs methylation of the GATA6 promoter, silencing GATA6 which is required for VCAM-1 transcription. Romidepsin (HDAC1/2 inhibitor) reduces VCAM-1 expression and atherosclerotic lesion development in Apoe-/- mice.\",\n      \"method\": \"Romidepsin treatment, HDAC1/2 siRNA, methylation-specific PCR for GATA6 promoter, ChIP for STAT3 at GATA6 promoter, STAT3 Lys685Arg mutation, DNMT1 co-IP, VCAM-1 expression, monocyte adhesion, in vivo Apoe-/- atherosclerosis model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal epigenetic methods, mutagenesis, Co-IP, and in vivo validation\",\n      \"pmids\": [\"33859766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VCAM1 expressed on haematopoietic stem cells and leukaemic stem cells functions as a 'don't-eat-me' signal to prevent phagocytic clearance by mononuclear phagocytes in the bone marrow; this activity is mechanistically regulated by β2-microglobulin MHC-I presentation on HSCs and paired Ig-like receptor-B (PIR-B) on phagocytes.\",\n      \"method\": \"Vcam1 conditional deletion in HSCs, haplotype-mismatched transplantation, phagocytosis assays, PIR-B blocking, MHC-I presentation analysis, AML mouse models with VCAM1 inhibition/deletion\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO plus receptor (PIR-B) blocking with mechanistic (MHC-I) validation and in vivo disease model\",\n      \"pmids\": [\"35210567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VCAM1-expressing endothelial cell-derived extracellular vesicles (enriched in miR-126) accumulate in the spleen and mobilize neutrophils to peripheral blood after myocardial infarction; CRISPR/Cas9 deletion of VCAM-1 in endothelial cells removes the neutrophil-mobilizing ability of these EVs.\",\n      \"method\": \"CRISPR/Cas9 VCAM-1 KO in endothelial cells, EV isolation and characterization, spleen neutrophil mobilization assay, miR-126 inhibition in vivo, myocardial infarction mouse model\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CRISPR genetic deletion in EV-producing cells with specific functional readout in vivo\",\n      \"pmids\": [\"35134856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IMPDH inhibition triggers overactivation of TLR-TRAF6-NF-κB signaling and upregulation of VCAM1 on leukaemic cells, contributing to the anti-leukemia effect; combined IMPDH inhibitor and TLR1/2 agonist treatment suppresses MLL-AF9-driven AML development.\",\n      \"method\": \"IMPDH inhibitor treatment, TLR pathway activation assay, VCAM1 expression measurement, in vivo AML mouse model, combination treatment\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway activation linked to VCAM1 upregulation with in vivo functional validation\",\n      \"pmids\": [\"36453131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DLL4 and VCAM-1 synergize during endothelial-to-hematopoietic transition to activate Notch signaling in nascent HSPCs and enhance progenitor T-cell output ~80-fold; VCAM-1 additionally promotes an inflammatory transcriptional program.\",\n      \"method\": \"Fully defined serum/feeder-free PSC differentiation system with individual protein titration, Notch reporter assay, transcriptional profiling, T-cell functional assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reconstituted defined system with Notch reporter and transcriptomic readouts\",\n      \"pmids\": [\"36001668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-33 induces VCAM1 expression in microglia; VCAM1 then directs microglial chemotaxis toward amyloid-β plaques by sensing plaque-associated ApoE. Disrupting the VCAM1-ApoE interaction abolishes microglial Aβ chemotaxis and decreases Aβ clearance.\",\n      \"method\": \"IL-33 stimulation, VCAM1 functional screening, microglial chemotaxis assay toward Aβ plaques, VCAM1-ApoE interaction blockade, in vivo AD mouse model\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional screening identified VCAM1 as chemotaxis mediator; interaction blockade and in vivo validation\",\n      \"pmids\": [\"37735240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Membrane-bound SCF clustering at the HSC–stromal interface synergizes with VCAM-1 on the bilayer to form a polarized HSC morphology with aggregated mSCF under a large protrusion, dramatically enhancing HSC adhesion. This synergy requires PI3K signaling and cytoskeletal reorganization, and it enhances nuclear retention of FOXO3a.\",\n      \"method\": \"Supported lipid bilayer (SLB) reconstitution of membrane-bound factors, fluorescence imaging, PI3K inhibition, cytoskeletal disruption, FOXO3a nuclear localization assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted membrane system with mechanistic inhibitor dissection and imaging\",\n      \"pmids\": [\"34402812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CAF-derived VCAM1 (upregulated by H. pylori infection via JAK/STAT1 signaling) molecularly interacts with integrin αvβ1/5 on gastric cancer cells to facilitate tumor invasion in vitro and in vivo.\",\n      \"method\": \"H. pylori infection of fibroblasts, RNA-seq, JAK/STAT1 inhibition, biolayer interferometry kinetic binding assay (VCAM1-integrin αvβ1/5), spheroid invasion assay, zebrafish xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct kinetic binding measurement plus in vitro and in vivo functional validation\",\n      \"pmids\": [\"32034307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Proinflammatory cytokines (TNF-α, IL-1β) induce VCAM-1 expression in proximal tubule cells via NF-κB signaling; VCAM-1 overexpression or TNF-α treatment increases immune cell (CD45+ splenocyte) adhesion to tubular monolayers, and NF-κB inhibition or Vcam1 genetic deletion suppresses this adhesion, establishing VCAM-1 as mediator of proximal tubule-immune cell cross-talk during AKI-to-CKD transition.\",\n      \"method\": \"TNF-α/IL-1β treatment of proximal tubule cells, NF-κB pharmacological inhibition, MyD88/TRIF genetic deletion, VCAM-1 overexpression, CD45+ splenocyte adhesion assay, single-cell transcriptomics of human AKI/CKD biopsies\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss of function with specific adhesion readout and pathway inhibition\",\n      \"pmids\": [\"39116349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Notch1 intracellular domain (Notch1ICD) in endothelial cells upregulates VCAM1 expression autonomously and amplifies IL-1β-induced VCAM1 induction through a Notch1-Jagged1 circuit; γ-secretase inhibition (blocking Notch1ICD generation) or Notch1/Jagged1 silencing reduce VCAM1 expression.\",\n      \"method\": \"Notch1ICD forced expression, Notch1/Jagged1 siRNA, γ-secretase inhibitor, VCAM1 expression measurement, luciferase reporter, in vivo chronic liver inflammation model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss of function with pathway inhibitor and in vivo validation\",\n      \"pmids\": [\"26646450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"β2-microglobulin-induced VCAM-1 expression in synovial fibroblasts requires IP3-mediated intracellular calcium release, PI-3 kinase, and intact actin cytoskeleton; chelating intracellular calcium or disrupting actin completely blocks VCAM-1 upregulation.\",\n      \"method\": \"β2m stimulation of synovial fibroblasts, Ca2+ chelation (BAPTA-AM), PLC inhibitor (U73122), IP3 inhibitor (2-APB), PI3K inhibitors (wortmannin/LY294002), cytoskeletal disruptors (cytochalasin D/latrunculin A), Western blot and immunohistochemistry\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological pathway dissections with specific VCAM-1 readout\",\n      \"pmids\": [\"11849381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Notch1-c-myc-VCAM1 signaling axis mediates HCC transendothelial migration and lung metastasis; c-myc transcriptionally upregulates VCAM1, which activates macrophage-dependent tumor cell transendothelial migration via macrophage α4β1 integrin-VCAM1 interaction. Depletion of VCAM1 reduces spontaneous lung metastasis without affecting primary tumor growth.\",\n      \"method\": \"N1ICD overexpression in rat liver progenitor cells, c-myc silencing, VCAM1 depletion, orthotopic transplantation, macrophage depletion, α4β1-integrin blockade, experimental metastasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic dissection in vivo with specific pathway components and functional metastasis readout\",\n      \"pmids\": [\"35256782\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VCAM1 is a transmembrane immunoglobulin superfamily adhesion molecule expressed on endothelial cells, stromal cells, and stem cells whose primary canonical function is binding α4 integrins (VLA-4/α4β1 and α4β7) on leukocytes and other cells via its immunoglobulin domains 1 and 4; ligation triggers NADPH oxidase–H₂O₂–PKCα endothelial signaling required for transendothelial migration, its expression is transcriptionally controlled by NF-κB, GATA factors, and Notch1 and epigenetically modulated by HDAC1/2-STAT3-DNMT1-mediated GATA6 promoter methylation and EZH2-dependent histone methylation, while post-transcriptional regulation by p38 MAPK and shedding by a zinc metalloprotease generates a soluble form; beyond leukocyte trafficking, VCAM1 regulates neural stem cell quiescence via intracellular domain–β-catenin signaling, serves as an innate immune 'don't-eat-me' checkpoint on HSCs through PIR-B recognition, directs microglial chemotaxis toward ApoE-decorated amyloid-β plaques, mediates chorioallantoic fusion during development, and its expression in brain endothelial cells at the blood-brain barrier propagates age-related neuroinflammation and cognitive decline.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"VCAM-1 was cloned as a novel cytokine-induced endothelial adhesion molecule that binds lymphocytes; it is a member of the immunoglobulin gene superfamily induced by IL-1 or TNF-alpha on human endothelial cells, mediating binding of mononuclear leukocytes but not neutrophils.\",\n      \"method\": \"Expression cloning by adhesion selection, transfection, mRNA induction assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with functional validation, highly cited foundational study\",\n      \"pmids\": [\"2688898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The human VCAM1 gene contains 9 exons spanning ~25 kb; alternative splicing of exon 5 produces two VCAM-1 precursors (6-domain and 7-domain forms). The promoter contains functional NF-κB, GATA, and AP1 binding sites.\",\n      \"method\": \"Genomic cloning, Southern blotting, chromosomal mapping (human-mouse hybrid cell lines and in situ hybridization), mRNA splicing analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic structural analysis with multiple orthogonal methods\",\n      \"pmids\": [\"1715583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"VCAM-1 binds B cell precursors to bone marrow fibroblasts via the integrin VLA-4 (CD49d/CD29); anti-VCAM-1 antibody blocked adhesion of normal B cell precursors, establishing the VLA-4/VCAM-1 axis in B cell precursor retention in bone marrow.\",\n      \"method\": \"Antibody blocking adhesion assays, flow cytometry, co-culture of B cell precursors with bone marrow fibroblasts\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal antibody blocking experiments with primary cells and cell lines\",\n      \"pmids\": [\"1715889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A seven-domain (long) form of human VCAM-1 was cloned; both six-domain and seven-domain forms support adhesion of VLA-4-expressing cell lines, with the long form being the major form expressed on endothelium.\",\n      \"method\": \"cDNA cloning, immunoprecipitation with deglycosylation, transfection of COS7 cells, adhesion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein biochemistry with functional validation\",\n      \"pmids\": [\"1707873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The VCAM-1 promoter is activated by TNF-alpha through two functional NF-κB sites at positions -77 and -63 bp; silencer elements between -1.641 kb and -288 bp restrict constitutive activity; NF-κB responsiveness is cell-type specific (present in endothelial cells but not Jurkat T cells).\",\n      \"method\": \"Deletion reporter (CAT) constructs transfected into bovine aortic endothelial cells, EMSA (gel retardation assays), TNF-alpha stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter deletion analysis with EMSA, replicated in subsequent studies\",\n      \"pmids\": [\"1379595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Functional NF-κB and GATA elements in the VCAM-1 core promoter are required for TNF-induced transcription in endothelial cells; new transcription (not mRNA stabilization) drives cytokine-induced VCAM-1 expression.\",\n      \"method\": \"Deletion reporter constructs, transfection into bovine aortic endothelial cells, nuclear run-on assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — transcriptional run-on assays combined with promoter deletion analysis\",\n      \"pmids\": [\"1281211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The murine VCAM1 gene has 10 exons spanning ~20 kb; exon 5 encodes a novel domain unique to murine VCAM-1 and inclusion by alternative splicing produces a truncated three-Ig-domain form anchored by a phosphatidylinositol linkage. The murine and human VCAM1 promoters share conserved NF-κB, Ets, and GATA binding sites.\",\n      \"method\": \"Genomic cloning, exon mapping, sequence analysis, alternative splicing characterization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic structural characterization\",\n      \"pmids\": [\"7507076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Genetic ablation of murine Vcam1 causes failure of allantois-chorion fusion at E8.5, resulting in defective placentation and embryonic lethality, revealing an essential developmental role for VCAM-1 in chorioallantoic fusion.\",\n      \"method\": \"Targeted homologous recombination (knockout mice), embryological analysis, histology\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined developmental phenotype\",\n      \"pmids\": [\"7530222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Both domain 1 and domain 4 of VCAM-1 independently support VLA-4 (α4β1)-dependent monocyte transendothelial migration; combined blockade of both domains is required for complete inhibition, and their relative contribution depends on the duration of endothelial IL-1 activation.\",\n      \"method\": \"Domain-specific anti-VCAM-1 mAb blocking assays, CHO cell transfection with 6-domain and 7-domain VCAM-1 constructs, monocyte migration assays under C5a gradient\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific antibody blockade combined with transfected cell systems\",\n      \"pmids\": [\"7545712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Membrane-bound VCAM-1 is converted to a soluble 100-kDa form by regulated metalloprotease-dependent proteolytic cleavage; EDTA and 1,10-phenanthroline (metalloprotease inhibitors) block this conversion, and phorbol ester induces shedding with concurrent loss of membrane-bound form.\",\n      \"method\": \"Biochemical characterization, metalloprotease inhibitor treatment, phorbol ester stimulation, immunoprecipitation of intracellular precursors and soluble forms in T cell clones\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitor experiments identifying metalloprotease-dependent shedding mechanism\",\n      \"pmids\": [\"7529789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TNF-alpha activates p38 MAP kinase in endothelial cells; p38 inhibition (SB203580) suppresses TNF-alpha-induced surface expression of VCAM-1 but not ICAM-1, without affecting VCAM-1 mRNA accumulation, indicating p38 regulates VCAM-1 at the post-transcriptional level.\",\n      \"method\": \"p38 MAPK inhibitor (SB203580), MAPKAP kinase 2 activity assays, Hsp27 phosphorylation, flow cytometry for surface expression, Northern blot for mRNA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal methods (kinase activity, protein expression, mRNA) in single study\",\n      \"pmids\": [\"9020057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"α9β1 integrin on neutrophils binds VCAM-1 and mediates stable adhesion and transendothelial neutrophil migration; α9β1 is highly expressed on neutrophils and contributes to chemotaxis across activated endothelium alongside α4 integrins.\",\n      \"method\": \"Cell adhesion assays with recombinant VCAM-1, antibody blocking of α9β1, transendothelial migration assays with TNF-alpha-activated HUVEC\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal adhesion and migration assays identifying novel integrin-VCAM-1 interaction\",\n      \"pmids\": [\"10209034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PPARα activators (fenofibrate, WY14643) inhibit TNF-alpha-induced VCAM-1 mRNA expression in human endothelial cells, in part by inhibiting NF-κB activation, and reduce monocyte adhesion; this identifies PPARα as a transcriptional regulator of VCAM-1.\",\n      \"method\": \"RT-PCR, transfection with VCAM-1 promoter deletion constructs, EMSA, monocyte adhesion assays, immunohistochemistry\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter analysis + EMSA + functional adhesion assays in multiple systems\",\n      \"pmids\": [\"10377075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"VCAM-1 on fibroblast-like synoviocytes (FLS) interacts with CD49d/CD29 (VLA-4) on B cells to rescue synovial B cells from apoptosis and upregulate Bcl-xL expression in a contact-dependent manner; anti-VCAM-1 antibody blocked both effects.\",\n      \"method\": \"Co-culture of synovial fluid B cells with FLS, antibody blocking, viability assays (trypan blue, annexin V, Hoechst staining), Western blot for Bcl-xL\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blocking with multiple viability readouts in a single study\",\n      \"pmids\": [\"10817566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RA synovial stromal cell VCAM-1 (CD106) interaction with CD49d/CD29 (VLA-4) on B cells induces Bcl-xL upregulation and protects B cells from apoptosis in a contact-dependent manner; anti-CD106 but not anti-CD54 antibody blocked these effects.\",\n      \"method\": \"Co-culture with stromal cell lines, antibody blocking, flow cytometry, Bcl-xL/Bcl-2 Western blot\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal blocking antibody experiments with defined molecular readout\",\n      \"pmids\": [\"10623863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"VCAM-1 expressed by bone marrow stromal cells is proteolytically cleaved by neutrophil serine proteases (neutrophil elastase and cathepsin G) during G-CSF-induced hematopoietic progenitor cell mobilization, enabling HSC egress.\",\n      \"method\": \"In vivo mouse mobilization model, immunohistochemistry, in vitro protease cleavage assays with recombinant VCAM-1 and purified neutrophil elastase/cathepsin G\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of protease cleavage combined with in vivo genetic evidence\",\n      \"pmids\": [\"11520773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"VCAM-1 interacts directly with moesin and ezrin (ERM proteins) and colocalizes with them at the apical endothelial surface. During leukocyte adhesion, VCAM-1, ICAM-1, activated moesin and ezrin cluster in an endothelial actin-rich docking structure that partially embraces the adherent leukocyte; this structure requires phosphoinositides and the Rho/ROCK pathway.\",\n      \"method\": \"In vitro direct binding assay (GST pulldown), live-cell imaging, immunofluorescence, siRNA-mediated knockdown, pharmacological inhibition of Rho/ROCK, dynamic fluorescence microscopy under flow\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding reconstituted in vitro + live imaging with functional validation\",\n      \"pmids\": [\"12082081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PMA-stimulated shedding of VCAM-1 from the cell surface is mediated specifically by TACE (ADAM17), a metalloproteinase that cleaves VCAM-1 near the transmembrane domain to produce soluble VCAM-1; cells from ADAM17-deficient mice lack PMA-induced VCAM-1 shedding.\",\n      \"method\": \"Metalloproteinase inhibitors, ADAM17-deficient mouse-derived cells, VCAM-1 shedding assays, comparison with E-selectin/PECAM-1/ICAM-1 shedding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO cells identifying specific protease, replicated with inhibitor pharmacology\",\n      \"pmids\": [\"12878595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Lymphocyte binding to VCAM-1 activates endothelial cell NADPH oxidase, generating ~1 μM H2O2, which in turn induces oxidation and activation of PKCα (phosphorylation at Thr638); this PKCα activation is required for VCAM-1-dependent leukocyte transendothelial migration.\",\n      \"method\": \"Dominant-negative PKCα overexpression, PKCα inhibitors (Rö-32-0432, Gö-6976), H2O2 scavenging, NADPH oxidase inhibition, anti-VCAM-1 antibody cross-linking, PKCα oxidation assay, spleen cell migration under laminar flow\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pharmacological and dominant-negative approaches converging on same mechanism\",\n      \"pmids\": [\"17056569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"miR-126 is expressed by endothelial cells and inhibits VCAM-1 expression; reduction of miR-126 increases TNF-alpha-stimulated VCAM-1 expression and enhances leukocyte adherence, while overexpression of miR-126 precursor decreases VCAM-1 levels.\",\n      \"method\": \"Transfection of endothelial cells with miR-126 inhibitor or precursor oligonucleotides, VCAM-1 protein/mRNA quantification, leukocyte adhesion assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation (gain and loss of function) with two orthogonal readouts\",\n      \"pmids\": [\"18227515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VCAM-1 aberrantly expressed on breast cancer cells tethers macrophages via α4-integrins; clustering of cancer cell surface VCAM-1, acting through Ezrin, activates PI3K/Akt signaling and protects cancer cells from TRAIL-induced apoptosis in leukocyte-rich microenvironments such as the lung.\",\n      \"method\": \"Co-culture of breast cancer cells with macrophages, antibody blocking of α4-integrins, dominant-negative Ezrin, Akt activation assays, TRAIL apoptosis assay, in vivo lung metastasis mouse model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic epistasis with dominant-negative constructs + in vivo validation\",\n      \"pmids\": [\"22014578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Aberrant VCAM-1 expression on breast cancer micrometastases in bone promotes transition from dormancy to overt metastasis by recruiting α4β1-positive monocytic osteoclast progenitors via VCAM-1/α4β1 interaction, elevating local osteoclast activity; anti-VCAM-1 and anti-α4 antibodies inhibit this process.\",\n      \"method\": \"Bone metastasis dormancy mouse model, NF-κB pathway manipulation, VCAM-1 overexpression, antibody blockade, osteoclast activity assays, in vivo imaging\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic manipulation + antibody blockade + in vivo model with mechanistic readout\",\n      \"pmids\": [\"22137794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IRF-1 and miR-126 reciprocally regulate VCAM-1 expression in response to triglyceride-rich lipoproteins (TGRL): proatherogenic TGRL increase IRF-1 and decrease miR-126, inducing VCAM-1; antiatherogenic TGRL do the opposite. Overexpression or silencing of IRF-1 or miR-126 recapitulates these effects.\",\n      \"method\": \"HAEC transfection with IRF-1 overexpression/silencing and miR-126 overexpression/silencing, VCAM-1 expression assay, monocyte arrest assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation of two regulators with functional monocyte arrest readout\",\n      \"pmids\": [\"22874466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Nuclear-localized FAK (kinase-inhibited) binds GATA4 transcription factor via its FERM domain, promoting CHIP E3 ligase-dependent polyubiquitination and degradation of GATA4; loss of GATA4 reduces VCAM-1 expression. Active FAK facilitates TNF-α-induced MAPK activation and GATA4 stability, thereby supporting VCAM-1 expression.\",\n      \"method\": \"Pharmacological FAK inhibition, conditional endothelial FAK knockout mice, nuclear fractionation, direct FAK-GATA4 binding assay, CHIP co-immunoprecipitation, GATA4 ubiquitination assay, in vivo heart vessel analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding, ubiquitination assay, genetic KO and pharmacological inhibition with in vivo validation\",\n      \"pmids\": [\"22734001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Metastatic tumor cell attachment induces endothelial VCAM-1 (dependent on tumor cell-clot/tissue factor formation); endothelial VCAM-1 recruits myeloid cells that support tumor cell survival and metastasis; VCAM-1 blocking antibody reduces myeloid recruitment and diminishes metastasis without affecting tumor cell adhesion.\",\n      \"method\": \"In vivo pulmonary metastasis mouse model, VCAM-1 blocking antibody, tissue factor pathway inhibitor/hirudin treatment, flow cytometry for myeloid cells, tumor cell survival assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blockade with mechanistic upstream pathway identification in vivo\",\n      \"pmids\": [\"23407548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"VLA-4 (α4β1) on leukocytes interacts with VCAM-1 to mediate reciprocal NF-κB activation in both leukemia cells and bone marrow mesenchymal stromal cells; this bidirectional signaling promotes stromal-mediated chemoresistance, reversible by VLA-4/VCAM-1 blockade or NF-κB inhibition.\",\n      \"method\": \"Genome-wide gene expression profiling of BM-MSCs, co-culture, NF-κB reporter assays, mutant IκBα overexpression, VLA-4 blocking antibody, in vivo human leukemia BM microenvironment model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (dominant-negative) and pharmacological blockade with in vivo validation\",\n      \"pmids\": [\"24599548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tumor-derived SPARC induces endothelial vascular permeability and cancer cell extravasation through VCAM-1 and p38 MAPK signaling; blocking VCAM-1 impedes SPARC-induced permeability and extravasation.\",\n      \"method\": \"Comparative proteomic analysis of melanoma secretomes, SPARC knockdown/overexpression, VCAM-1 blocking antibody, vascular permeability assays, lung metastasis mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic manipulation of SPARC and antibody blockade of VCAM-1 with in vivo validation\",\n      \"pmids\": [\"25925867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VCAM-1 is a TGF-β1-inducible gene in lung fibroblasts (via transcriptional induction, not mRNA stabilization); VCAM-1 depletion inhibits fibroblast proliferation, causing G2/M and S phase arrest associated with reduced phospho-ERK1/2 and cyclin D1.\",\n      \"method\": \"TGF-β1 treatment, VCAM-1 siRNA depletion, mRNA stability assays, cell cycle analysis, Western blot for phospho-ERK1/2 and cyclin D1\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with cell cycle and signaling readouts\",\n      \"pmids\": [\"26386411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"oxLDL induces NF-κB activation and VCAM-1 expression through FAK-dependent activation of RSK (p90 ribosomal S6 kinase), which activates IKKβ; transgenic mice with endothelial-specific kinase-dead FAK show reduced RSK activity, decreased VCAM-1 expression, and reduced macrophage accumulation in atherosclerotic regions.\",\n      \"method\": \"RSK inhibitors, FAK kinase-dead transgenic mice, IKKβ activation assays, NF-κB reporter, monocyte adhesion assay, atherosclerosis model\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological + genetic (kinase-dead transgene) with in vivo atherosclerosis validation\",\n      \"pmids\": [\"26906414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VCAM-1 expression in glioblastoma depends on EGFR expression, and is regulated via the p38/STAT3 signaling pathway; miR-181b, via protein phosphatase 2A-modulated SP-1 dephosphorylation, controls EGFR-dependent VCAM-1 expression and thereby monocyte adhesion to GBM cells through integrin α4β1.\",\n      \"method\": \"EGFR inhibition, VCAM-1 knockdown, integrin α4β1 blocking, miR-181b overexpression/inhibition, PP2A assay, SP-1 phosphorylation Western blot, 2D/3D co-culture adhesion assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling components manipulated with functional adhesion readout\",\n      \"pmids\": [\"28459461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VCAM-1 signals through its intracellular domain to regulate β-catenin signaling in embryonic radial glial cells (RGCs) in a context-dependent manner; loss of VCAM-1 in RGCs stimulates premature neuronal differentiation and prevents quiescence, depleting the embryonic origin of postnatal neural stem cells.\",\n      \"method\": \"Conditional Vcam1 knockout mice (region- and stage-specific), β-catenin reporter assays, BrdU labeling, clonal analysis, in vitro neural stem cell assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic KO with defined cellular phenotype and molecular pathway (β-catenin) identified\",\n      \"pmids\": [\"28728023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VCAM-1 synergizes with Delta-like 4 (DLL4) to enhance Notch signaling in hematopoietic stem and progenitor cells and promote T-lineage differentiation; VCAM-1 additionally activates an inflammatory transcriptional program in nascent HSPCs.\",\n      \"method\": \"Defined stromal cell-free in vitro T cell differentiation system, DLL4/VCAM-1 protein presentation on surfaces, Notch reporter assays, flow cytometry for T cell progenitors, in vivo thymus colonization\",\n      \"journal\": \"Nature methods\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reconstituted defined niche system with Notch signaling readout\",\n      \"pmids\": [\"28394335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VCAM-1+ macrophage-like 'usher' cells patrol the inner surface of the venous plexus in zebrafish caudal haematopoietic tissue, interact with HSPCs via ITGA4, and direct HSPC retention at vascular homing hotspots.\",\n      \"method\": \"Advanced live imaging in zebrafish, cell-labelling system, ITGA4 blocking, in vivo loss-of-function\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — high-resolution live imaging with molecular (ITGA4) blocking in vivo\",\n      \"pmids\": [\"30455424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Brain endothelial VCAM-1 mediates the detrimental effects of aged plasma on young brains: aged plasma elevates VCAM-1 on BECs; anti-VCAM-1 antibody administration or genetic ablation of Vcam1 in BECs counteracts microglial reactivity and cognitive deficits induced by aged plasma in young mice.\",\n      \"method\": \"Systemic anti-VCAM-1 antibody, conditional endothelial Vcam1 KO mice, parabiosis/plasma transfer model, microglial activation assays, cognitive behavioral tests\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and antibody blockade with in vivo functional (cognitive) readout\",\n      \"pmids\": [\"31086348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"M2 macrophage VLA-4 (α4β1) engagement with endothelial VCAM-1 induces vascular permeability through a RAC1/ROS/PYK2 phosphorylation/VE-cadherin phosphorylation cascade; downregulation of VLA-4 or VCAM-1 reduces RAC1 and ROS, decreases p-PYK2 and p-VE-cadherin, and enhances barrier integrity. Targeting the VLA-4/VCAM-1 axis abrogates ascites formation in vivo.\",\n      \"method\": \"VLA-4 overexpression/knockdown, VCAM-1 overexpression in ECs, RAC1/ROS/PYK2/VE-cadherin signaling assays, vascular permeability assay, in vivo ovarian cancer ascites model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined molecular cascade with multiple orthogonal perturbations and in vivo validation\",\n      \"pmids\": [\"33295887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HDAC1/2 promote endothelial VCAM-1 expression by suppressing STAT3 acetylation-dependent methylation (via DNMT1) of the GATA6 promoter; HDAC1/2 inhibition increases STAT3 acetylation, promotes STAT3-DNMT1 interaction, leads to GATA6 promoter hypermethylation, reduces GATA6 and VCAM-1 expression, and attenuates atherosclerosis.\",\n      \"method\": \"HDAC1/2 siRNA, Romidepsin treatment, methylation-specific PCR, ChIP for STAT3 at GATA6 promoter, STAT3 Lys685Arg acetylation-blocking mutant, DNMT1 co-immunoprecipitation, ApoE-/- mouse atherosclerosis model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic epistasis with mutant constructs, ChIP, and in vivo validation\",\n      \"pmids\": [\"33859766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VCAM-1 on haematopoietic stem cells serves as a 'don't-eat-me' signal providing innate immune tolerance; this function is regulated by β2-microglobulin/MHC-I presentation on HSCs and paired Ig-like receptor-B (PIR-B) on phagocytes. VCAM-1 deletion in haplotype-mismatched settings impairs HSC engraftment due to phagocytic clearance.\",\n      \"method\": \"Vcam1 conditional KO, haplotype-mismatch transplantation, MHC-I/β2m blocking, PIR-B KO phagocytes, phagocytosis assays, in vivo HSC engraftment assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple mechanistic components (MHC-I, PIR-B) and in vivo engraftment readout\",\n      \"pmids\": [\"35210567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DLL4 and VCAM-1 synergize to activate Notch signaling in nascent HSPCs during endothelial-to-haematopoietic transition, enhancing T cell progenitor output ~80-fold; VCAM-1 additionally promotes an inflammatory transcriptional program in HSPCs.\",\n      \"method\": \"Defined serum/feeder-free PSC differentiation system, single-protein presentation, Notch reporter, transcriptomic analysis, flow cytometry, in vivo T cell maturation\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined reconstituted system with Notch signaling and transcriptomic readouts\",\n      \"pmids\": [\"36001668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-33 induces VCAM-1 in microglia, which promotes microglial chemotaxis toward amyloid-β plaques by sensing plaque-associated ApoE; disrupting the VCAM-1-ApoE interaction abolishes microglial Aβ chemotaxis and decreases Aβ clearance.\",\n      \"method\": \"IL-33 stimulation of microglia, VCAM-1 functional screening, VCAM-1-ApoE interaction blocking, Aβ chemotaxis assays, in vivo Alzheimer's disease mouse model\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional screening identifying VCAM-1 as chemotactic receptor for ApoE, blocking validates specificity\",\n      \"pmids\": [\"37735240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Membrane-bound SCF and VCAM-1 synergistically regulate HSC morphology: HSCs cluster membrane-bound SCF at the HSC-bilayer interface and form a polarized morphology with large protrusion; VCAM-1 dramatically enhances HSC adhesion to the bilayer through a mechanism requiring PI3K signaling and cytoskeletal reorganization, and the synergy enhances nuclear retention of FOXO3a.\",\n      \"method\": \"Supported lipid bilayer reconstitution system, PI3K inhibitors, cytoskeletal disruption, FOXO3a localization by immunofluorescence, HSC adhesion force measurements\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted bilayer system with PI3K epistasis and defined morphological/signaling readout\",\n      \"pmids\": [\"34402812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Notch1 intracellular domain (N1ICD) in endothelial cells upregulates Jagged1 and directly induces VCAM-1 expression in the absence of inflammatory cytokines; Notch1/Jagged1 circuit amplifies IL-1β-induced VCAM-1 induction. γ-Secretase inhibition and Notch1/Jagged1 silencing abrogate IL-1β-mediated VCAM-1 induction.\",\n      \"method\": \"γ-Secretase inhibitor, Notch1/Jagged1 siRNA silencing, forced N1ICD expression, VCAM-1 quantification, in vivo chronic liver inflammation model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional Notch1 manipulation with VCAM-1 as direct transcriptional target readout\",\n      \"pmids\": [\"26646450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"H. pylori infection increases VCAM-1 expression in cancer-associated fibroblasts via JAK/STAT1 signaling; CAF-derived VCAM-1 physically interacts with integrin αvβ1/5 on gastric cancer cells to facilitate tumor invasion in vitro and in vivo.\",\n      \"method\": \"RNA-seq of H. pylori-infected fibroblasts, JAK/STAT1 inhibitors, biolayer interferometry for VCAM1-integrin binding kinetics, zebrafish xenograft invasion model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding kinetics assay (BLI) + genetic manipulation + in vivo xenograft model\",\n      \"pmids\": [\"32034307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"H3K18 lactylation in the gastric cancer tumor microenvironment transcriptionally activates VCAM-1; VCAM-1 in turn activates AKT-mTOR signaling to promote GC cell proliferation and migration, and upregulates CXCL1 via AKT-mTOR to recruit mesenchymal stem cells and M2 macrophages.\",\n      \"method\": \"H3K18 lactylation ChIP, VCAM-1 overexpression/knockdown, AKT-mTOR pathway inhibitors, CXCL1 quantification, macrophage/MSC recruitment assays, GC mouse models\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epigenetic ChIP combined with pathway inhibition and recruitment functional assays\",\n      \"pmids\": [\"38461905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Proinflammatory cytokines (TNF-α and IL-1β) induce NF-κB-dependent VCAM-1 expression in proximal tubule cells; tubular VCAM-1 overexpression or TNF-α stimulation increases splenocyte adhesion to tubular monolayers; pharmacological NF-κB inhibition or genetic Vcam1 deletion suppresses this tubule-immune cell adhesion.\",\n      \"method\": \"TNF-α/IL-1β treatment of immortalized mouse proximal tubular cells and primary renal cells, NF-κB inhibitors, MyD88/TRIF double-KO cells, VCAM-1 overexpression, splenocyte adhesion assay, single-cell transcriptomics of patient biopsies\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and overexpression with functional adhesion readout in multiple cell systems\",\n      \"pmids\": [\"39116349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VCAM-1-bearing endothelial cell-derived extracellular vesicles (EVs) are rapidly released after myocardial infarction and accumulate in the spleen, where they induce inflammatory gene expression and mobilize splenic neutrophils to peripheral blood; CRISPR/Cas9 deletion of VCAM-1 in endothelial cells removes the ability of EVs to provoke neutrophil mobilization.\",\n      \"method\": \"CRISPR/Cas9 VCAM-1-deficient endothelial cells, EV characterization (size/marker), in vivo splenic neutrophil mobilization assay, miRNA-126 in vivo inhibition, MI mouse model\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR genetic deletion in EV-producing cells with in vivo functional readout\",\n      \"pmids\": [\"35134856\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VCAM-1 is a cytokine-inducible, NF-κB/GATA-regulated immunoglobulin superfamily transmembrane glycoprotein on endothelial and other cells that mediates leukocyte, HSPC, and cancer cell adhesion primarily through VLA-4 (α4β1) and α9β1 integrins; its extracellular domain is shed as a soluble form by ADAM17/TACE and neutrophil serine proteases; its cytoplasmic tail signals through NADPH oxidase-generated H2O2, PKCα oxidation, Ezrin/moesin-dependent actin docking structures, and β-catenin pathways; additional upstream regulators include p38 MAPK (post-transcriptional), FAK-GATA4 (nuclear ubiquitination), HDAC1/2-STAT3-GATA6 (epigenetic), miR-126, and Notch1-Jagged1, collectively positioning VCAM-1 as a multi-context adhesion and signaling hub in inflammation, hematopoiesis, development, neurodegeneration, and cancer metastasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"VCAM1 is a transmembrane immunoglobulin-superfamily adhesion receptor that orchestrates leukocyte-endothelial interactions, hematopoietic stem cell niche retention, neural stem cell quiescence, and developmental morphogenesis through engagement of α4 integrins and other partners. The 7-domain isoform predominates on endothelium, where domains 1 and 4 each independently bind VLA-4 (α4β1 integrin) to support leukocyte adhesion and transendothelial migration; VCAM-1 cross-linking activates an endothelial NADPH oxidase–H₂O₂–PKCα signaling cascade required for this migration, while a parallel RAC1–ROS–PYK2–VE-cadherin pathway regulates endothelial barrier integrity [PMID:1707873, PMID:7545712, PMID:17056569, PMID:33295887]. Transcription is driven by NF-κB, GATA factors, and Notch1 and is epigenetically modulated by HDAC1/2–STAT3–DNMT1-mediated GATA6 promoter methylation and EZH2-dependent histone methylation, with post-transcriptional control by p38 MAPK and proteolytic shedding by a zinc metalloprotease generating a soluble form [PMID:7507076, PMID:9020057, PMID:7529789, PMID:33859766, PMID:28500253]. Beyond leukocyte trafficking, VCAM1 maintains neural stem cell quiescence through intracellular-domain–β-catenin signaling, functions as an innate immune 'don't-eat-me' signal on HSCs via PIR-B recognition, directs microglial chemotaxis toward ApoE-decorated amyloid-β plaques, mediates chorioallantoic fusion during embryogenesis, and propagates age-related neuroinflammation at the blood–brain barrier [PMID:28728023, PMID:35210567, PMID:37735240, PMID:7530222, PMID:31086348].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Establishing that VCAM1 exists in two alternatively spliced isoforms (6- and 7-domain) that both support VLA-4-dependent adhesion resolved the molecular identity of the endothelial ligand for α4β1 integrin.\",\n      \"evidence\": \"cDNA cloning, COS7 transfection, immunoprecipitation, and cell adhesion assay\",\n      \"pmids\": [\"1707873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of the two isoforms to different adhesion contexts not resolved\", \"Structural basis of domain–integrin contact not determined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping the murine gene structure (10 exons, one Ig domain per exon) and identifying conserved NF-κB, Ets, and GATA sites in the promoter established the transcriptional regulatory framework for cytokine-inducible VCAM1 expression.\",\n      \"evidence\": \"Genomic cloning, sequencing, exon mapping, and promoter analysis; antibody-blocking adhesion assays on cytokine-stimulated endothelium\",\n      \"pmids\": [\"7507076\", \"7680963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional contribution of individual TF sites not tested by mutagenesis at this point\", \"GPI-anchored 3-domain isoform function unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Genetic ablation of VCAM1 causing embryonic lethality from failed chorioallantoic fusion, combined with the demonstration that domains 1 and 4 each independently support transendothelial migration, revealed both a non-immune developmental requirement and the structural redundancy within the 7-domain form.\",\n      \"evidence\": \"Gene knockout with embryo histology; CHO reconstitution with domain-specific antibody blockade; metalloprotease inhibitor identification of shedding mechanism\",\n      \"pmids\": [\"7530222\", \"7545712\", \"7529789\", \"8640376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the zinc metalloprotease responsible for shedding not determined\", \"Mechanism by which VCAM1 drives allantois–chorion fusion unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that p38 MAPK regulates VCAM-1 surface expression post-transcriptionally (without affecting mRNA) identified a translational or trafficking control layer distinct from NF-κB-driven transcription.\",\n      \"evidence\": \"p38 inhibitor SB203580 in TNF-stimulated endothelial cells with parallel mRNA (Northern) and protein (ELISA) readouts\",\n      \"pmids\": [\"9020057\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p38 acts on translation, stabilization, or trafficking not distinguished\", \"In vivo relevance not demonstrated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that VCAM-1/VLA-4 contact on synovial stromal cells rescues B cells from apoptosis via Bcl-xL induction revealed a pro-survival signaling function transmitted through the integrin, extending VCAM1 biology beyond migration.\",\n      \"evidence\": \"Co-culture with reciprocal antibody blockade; annexin V apoptosis assay; Bcl-xL Western blot\",\n      \"pmids\": [\"10623863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway downstream of VLA-4 leading to Bcl-xL not mapped\", \"Contribution to B-cell survival in vivo not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Elucidation of the endothelial VCAM-1 outside-in signaling cascade — NADPH oxidase activation generating H₂O₂, which oxidizes and activates PKCα at Thr638 — established the first intracellular mechanism by which VCAM-1 on endothelium actively promotes lymphocyte transmigration.\",\n      \"evidence\": \"VCAM-1 antibody cross-linking, NADPH oxidase/H₂O₂ inhibition, dominant-negative PKCα, transendothelial migration under flow\",\n      \"pmids\": [\"17056569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical link between VCAM-1 cytoplasmic domain and NADPH oxidase not identified\", \"Role of specific NOX isoforms not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that nuclear FAK promotes GATA4 ubiquitination via CHIP E3 ligase to suppress VCAM-1 transcription, and that miR-126 and IRF-1 reciprocally regulate VCAM-1, revealed multiple upstream regulatory nodes converging on VCAM1 transcription.\",\n      \"evidence\": \"FAK-GATA4 Co-IP, in vitro ubiquitination, in vivo FAK ablation; IRF-1 gain/loss-of-function and miR-126 manipulation in HAECs\",\n      \"pmids\": [\"22734001\", \"22874466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FAK nuclear import is regulated remains unclear\", \"Whether IRF-1 and miR-126 converge on the same mRNA pool not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Multiple studies expanded the signaling networks controlling VCAM1: Notch1ICD autonomously upregulates VCAM1 via a Jagged1 amplification loop, EZH2 recruited by LINC00341 epigenetically silences VCAM1 under laminar shear, and FAK–RSK–IKKβ–NF-κB drives oxLDL-induced VCAM1 in atherosclerosis.\",\n      \"evidence\": \"Notch1ICD overexpression/γ-secretase inhibition; ChIP for EZH2 at VCAM1 promoter; endothelial FAK kinase-dead transgenic mice with atherosclerosis model\",\n      \"pmids\": [\"26646450\", \"28500253\", \"26906414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Notch1 binding site on VCAM1 promoter not mapped\", \"How laminar flow induces LINC00341 is unknown\", \"Whether EZH2-mediated H3K27me3 and NF-κB activation are mutually exclusive at the VCAM1 locus not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Two landmark findings revealed non-endothelial VCAM1 functions: its intracellular domain signals through β-catenin to maintain neural stem cell quiescence, and VCAM1 synergizes with DLL4 to enhance Notch signaling and progenitor T-cell differentiation in a reconstituted hematopoietic niche.\",\n      \"evidence\": \"Conditional VCAM1 KO in radial glia with BrdU/EdU labeling and β-catenin reporter; engineered stromal-free niche with DLL4+VCAM1, Notch reporter, in vivo thymus colonization\",\n      \"pmids\": [\"28728023\", \"28394335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding partner of VCAM1 intracellular domain that activates β-catenin not identified\", \"Mechanism of VCAM1-Notch synergy (cis vs trans) not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that brain endothelial VCAM1 mediates age-related neuroinflammation and cognitive decline — with both genetic ablation and antibody blockade reversing these phenotypes — established VCAM1 as a druggable mediator of brain aging.\",\n      \"evidence\": \"BEC-specific Vcam1 conditional KO, anti-VCAM1 antibody, heterochronic plasma transfer, microglial activation and cognitive behavioral tests\",\n      \"pmids\": [\"31086348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Plasma factor that induces BEC VCAM1 during aging not identified\", \"Whether leukocyte transmigration or soluble VCAM1 shedding drives the aging phenotype not distinguished\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapping the VCAM1–RAC1–ROS–PYK2–VE-cadherin cascade in endothelium and the HDAC1/2–STAT3–DNMT1–GATA6 epigenetic circuit controlling VCAM1 transcription provided therapeutic targets for vascular permeability and atherosclerosis, respectively.\",\n      \"evidence\": \"VCAM1 overexpression with RAC1/ROS/PYK2 pathway dissection and in vivo ascites model; romidepsin treatment, GATA6 promoter methylation-specific PCR, STAT3 mutagenesis, Apoe−/− atherosclerosis model\",\n      \"pmids\": [\"33295887\", \"33859766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural interaction between VCAM1 cytoplasmic domain and RAC1 regulators not shown\", \"Whether HDAC1/2 inhibition affects VCAM1 in non-endothelial cells not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"VCAM1 on HSCs was identified as an innate immune 'don't-eat-me' signal recognized by PIR-B on phagocytes, with MHC-I/β2m regulating this axis; this finding also revealed that leukemic stem cells co-opt this mechanism to evade phagocytosis.\",\n      \"evidence\": \"Conditional Vcam1 deletion in HSCs, haplotype-mismatched transplantation, phagocytosis assays, PIR-B blocking, AML models\",\n      \"pmids\": [\"35210567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VCAM1 directly binds PIR-B or acts indirectly through MHC-I not conclusively resolved\", \"Therapeutic window for targeting VCAM1 on LSCs without ablating normal HSCs not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that IL-33-induced microglial VCAM1 senses plaque-associated ApoE to direct chemotaxis toward amyloid-β plaques established VCAM1 as a chemotactic receptor on microglia, expanding its role beyond adhesion to directional cell migration.\",\n      \"evidence\": \"Functional screening, microglial chemotaxis assay, VCAM1–ApoE interaction blockade, AD mouse model\",\n      \"pmids\": [\"37735240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface between VCAM1 and ApoE not structurally defined\", \"Whether VCAM1 mediates phagocytic clearance of Aβ or only chemotaxis not distinguished\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: (1) the identity of the VCAM1 intracellular domain binding partner that engages β-catenin signaling; (2) the precise metalloprotease(s) responsible for shedding in different tissue contexts; (3) structural resolution of the VCAM1–PIR-B and VCAM1–ApoE interactions; (4) how endothelial versus non-endothelial VCAM1 outside-in signaling pathways diverge.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of VCAM1–PIR-B or VCAM1–ApoE complex\", \"VCAM1 cytoplasmic domain interactome not systematically mapped\", \"Relative contributions of membrane-bound vs soluble VCAM1 in aging not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 2, 4, 6, 8, 20, 31]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [9, 23, 18]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [25, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 4, 5, 9, 22, 25]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 26]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 9, 22, 25, 32]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 4, 6, 8, 20, 23, 31]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 17, 18, 19, 23, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 18, 19, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 25, 27, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ITGA4\",\n      \"ITGB1\",\n      \"APOE\",\n      \"LILRB3\",\n      \"DLL4\",\n      \"SPARC\",\n      \"B2M\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"VCAM-1 is a cytokine-inducible immunoglobulin superfamily transmembrane glycoprotein that serves as a central adhesion and signaling hub on endothelial, stromal, and other cell types, mediating leukocyte, hematopoietic stem cell, and cancer cell interactions through binding VLA-4 (α4β1) and α9β1 integrins [PMID:2688898, PMID:10209034]. Its transcription is driven by NF-κB and GATA elements in the proximal promoter and is further regulated by Notch1/Jagged1 signaling, HDAC1/2–STAT3–GATA6 epigenetic circuits, miR-126, and FAK–GATA4 nuclear ubiquitination pathways [PMID:1379595, PMID:18227515, PMID:33859766, PMID:22734001, PMID:26646450]. Engagement of VCAM-1 by integrin-bearing leukocytes activates endothelial NADPH oxidase–derived H₂O₂, PKCα oxidation, and Ezrin/moesin-dependent actin docking structures that facilitate transendothelial migration, while its extracellular domain is proteolytically shed by ADAM17 and neutrophil serine proteases to modulate adhesion in inflammation and hematopoietic progenitor mobilization [PMID:17056569, PMID:12082081, PMID:12878595, PMID:11520773]. Beyond classical leukocyte trafficking, VCAM-1 regulates embryonic chorioallantoic fusion, neural stem cell quiescence via β-catenin signaling, HSC immune tolerance as a 'don't-eat-me' signal, brain endothelial aging-associated neuroinflammation, and cancer cell survival and metastasis through PI3K/Akt and AKT–mTOR pathways [PMID:7530222, PMID:28728023, PMID:35210567, PMID:31086348, PMID:22014578].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of VCAM-1 as a new cytokine-inducible endothelial adhesion molecule for lymphocytes established it as a member of the immunoglobulin superfamily mediating selective leukocyte recruitment.\",\n      \"evidence\": \"Expression cloning by adhesion selection from IL-1/TNF-α–stimulated HUVEC cDNA library\",\n      \"pmids\": [\"2688898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand on the leukocyte side not yet identified\", \"In vivo function unknown\", \"Signaling capacity of the cytoplasmic tail uncharacterized\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Genomic characterization revealed alternative splicing producing 6- and 7-domain isoforms, and identification of NF-κB/GATA/AP1 promoter elements explained cytokine-inducible transcription, while the VLA-4 (α4β1) integrin was identified as the counter-receptor mediating B cell precursor retention in bone marrow.\",\n      \"evidence\": \"Genomic cloning, promoter-reporter analysis, EMSA, antibody-blocking adhesion assays with bone marrow fibroblasts and B cell precursors\",\n      \"pmids\": [\"1715583\", \"1707873\", \"1715889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative functional contribution of 6- vs 7-domain isoforms in vivo unclear\", \"Other integrin counter-receptors not yet explored\", \"Mechanism of NF-κB cell-type specificity not resolved\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Detailed promoter dissection confirmed that tandem NF-κB sites and a GATA element are essential for TNF-α–induced transcription, ruling out mRNA stabilization as the primary induction mechanism.\",\n      \"evidence\": \"Deletion reporter constructs, nuclear run-on assays, EMSA in bovine aortic endothelial cells\",\n      \"pmids\": [\"1379595\", \"1281211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the GATA family member driving endothelial expression unknown\", \"Chromatin-level regulation not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Three key mechanistic advances: (1) Vcam1 knockout mice revealed embryonic lethality from failed chorioallantoic fusion, establishing a non-immune developmental role; (2) domains 1 and 4 were shown to independently mediate VLA-4–dependent monocyte transmigration; (3) regulated metalloprotease-dependent ectodomain shedding was identified as a mechanism generating soluble VCAM-1.\",\n      \"evidence\": \"Targeted gene disruption in mice; domain-specific mAb blocking in transmigration assays; metalloprotease inhibitor studies with immunoprecipitation\",\n      \"pmids\": [\"7530222\", \"7545712\", \"7529789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the sheddase not yet determined\", \"Whether placentation failure reflects adhesion vs signaling function unknown\", \"Physiological role of soluble VCAM-1 undefined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Discovery that p38 MAPK selectively controls VCAM-1 surface expression post-transcriptionally (without affecting mRNA levels) revealed a layer of regulation beyond NF-κB–driven transcription.\",\n      \"evidence\": \"p38 inhibitor SB203580 in TNF-α–stimulated endothelial cells with parallel mRNA and surface protein quantification\",\n      \"pmids\": [\"9020057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Post-transcriptional mechanism (translation, trafficking, or stability) not specified\", \"Only pharmacological inhibitor used, no genetic confirmation\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of α9β1 as a second integrin counter-receptor on neutrophils expanded VCAM-1's adhesion repertoire beyond VLA-4, explaining neutrophil interaction that was initially thought absent.\",\n      \"evidence\": \"Recombinant VCAM-1 adhesion assays and α9β1 antibody blocking in transendothelial migration\",\n      \"pmids\": [\"10209034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of α9β1 vs α4β1 in vivo not delineated\", \"Structural basis of dual-integrin recognition unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Direct interaction of VCAM-1 with ezrin and moesin was demonstrated, and live imaging revealed VCAM-1/ICAM-1/ERM actin-rich docking structures that embrace adherent leukocytes, establishing a cytoskeletal signaling function for VCAM-1's cytoplasmic tail.\",\n      \"evidence\": \"GST pulldown for direct binding, live-cell dynamic fluorescence microscopy under flow, pharmacological inhibition of Rho/ROCK\",\n      \"pmids\": [\"12082081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cytoplasmic tail residues mediating ERM binding not mapped\", \"Whether docking structures are required for transmigration vs firm adhesion not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ADAM17 (TACE) was identified as the specific metalloproteinase responsible for PMA-stimulated VCAM-1 ectodomain shedding, resolving the identity of the sheddase.\",\n      \"evidence\": \"ADAM17-deficient mouse-derived cells lack PMA-induced VCAM-1 shedding; metalloproteinase inhibitor pharmacology\",\n      \"pmids\": [\"12878595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage site not precisely mapped\", \"Whether ADAM17 mediates constitutive shedding or only stimulated shedding unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Leukocyte binding to VCAM-1 was shown to activate endothelial NADPH oxidase, generating H₂O₂ that oxidizes and activates PKCα, which is required for transendothelial migration—linking VCAM-1 engagement to a reactive oxygen species signaling cascade.\",\n      \"evidence\": \"Dominant-negative PKCα, PKCα inhibitors, NADPH oxidase inhibition, anti-VCAM-1 cross-linking in endothelial cells under laminar flow\",\n      \"pmids\": [\"17056569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How VCAM-1 cytoplasmic tail couples to NADPH oxidase activation not defined\", \"Whether PKCα oxidation is the sole downstream effector unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"miR-126 was established as a post-transcriptional negative regulator of VCAM-1 in endothelial cells, with bidirectional gain- and loss-of-function demonstrating its role in tuning leukocyte adhesion.\",\n      \"evidence\": \"Transfection of miR-126 inhibitor/precursor in endothelial cells with VCAM-1 protein/mRNA quantification and leukocyte adhesion assay\",\n      \"pmids\": [\"18227515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether miR-126 directly targets VCAM-1 3ʹ UTR or acts indirectly not fully resolved\", \"In vivo significance in inflammation not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"VCAM-1 was repurposed in cancer: aberrant expression on breast cancer cells tethers macrophages via α4-integrins, activating Ezrin–PI3K/Akt pro-survival signaling in cancer cells; separately, VCAM-1 on bone micrometastases recruits osteoclast progenitors to switch dormancy to overt metastasis.\",\n      \"evidence\": \"Dominant-negative Ezrin, α4 blocking, TRAIL apoptosis and Akt assays, bone metastasis dormancy mouse models\",\n      \"pmids\": [\"22014578\", \"22137794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VCAM-1–Ezrin–Akt axis operates in non-breast cancers untested\", \"Mechanism of VCAM-1 transcriptional reactivation in cancer cells not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Upstream regulatory complexity expanded: FAK–GATA4 nuclear pathway controls VCAM-1 via CHIP-mediated GATA4 ubiquitination, and IRF-1/miR-126 reciprocal regulation links lipid metabolism to VCAM-1 in atherogenesis.\",\n      \"evidence\": \"Conditional endothelial FAK KO, direct FAK–GATA4 binding, CHIP co-IP and ubiquitination assay; IRF-1/miR-126 bidirectional manipulation with monocyte arrest readout\",\n      \"pmids\": [\"22734001\", \"22874466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GATA4 or GATA6 predominates in different vascular beds unclear\", \"FAK–GATA4 mechanism not tested outside cardiac endothelium\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Notch1 intracellular domain was shown to directly induce VCAM-1 in the absence of inflammatory cytokines, adding a developmental signaling pathway to VCAM-1 regulation; concurrently, tumor-derived SPARC was found to induce endothelial VCAM-1 via p38 MAPK to promote cancer cell extravasation.\",\n      \"evidence\": \"Forced N1ICD expression, γ-secretase inhibition, Notch1/Jagged1 siRNA; SPARC manipulation with VCAM-1 blocking in melanoma lung metastasis model\",\n      \"pmids\": [\"26646450\", \"25925867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Notch1 binds the VCAM-1 promoter directly or acts through intermediaries not shown\", \"Generalizability of SPARC–VCAM-1 axis across tumor types unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"VCAM-1's intracellular signaling was shown to regulate β-catenin in embryonic radial glial cells, maintaining neural stem cell quiescence; separately, VCAM-1 synergized with DLL4 to enhance Notch signaling in HSPCs for T-lineage differentiation.\",\n      \"evidence\": \"Conditional Vcam1 KO in embryonic brain, β-catenin reporter, BrdU labeling; defined stromal-free DLL4/VCAM-1 co-presentation system with Notch reporter\",\n      \"pmids\": [\"28728023\", \"28394335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How VCAM-1 cytoplasmic domain activates β-catenin mechanistically unknown\", \"Whether VCAM-1 directly potentiates Notch receptor activation or acts through co-signaling unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Brain endothelial VCAM-1 was identified as a mediator of aging-associated neuroinflammation: aged plasma elevates brain endothelial VCAM-1, and genetic ablation or antibody blockade reverses microglial reactivity and cognitive decline in young mice receiving aged plasma.\",\n      \"evidence\": \"Conditional endothelial Vcam1 KO, anti-VCAM-1 antibody, parabiosis/plasma transfer, cognitive behavioral tests\",\n      \"pmids\": [\"31086348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Factor(s) in aged plasma responsible for VCAM-1 induction not identified\", \"Whether VCAM-1 signals to microglia directly or recruits peripheral immune cells not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Two new signaling cascades were delineated: (1) macrophage VLA-4/endothelial VCAM-1 engagement activates RAC1/ROS/PYK2/VE-cadherin phosphorylation to induce vascular permeability; (2) VCAM-1 with membrane-bound SCF on lipid bilayers synergistically promotes HSC adhesion, polarized morphology, and FOXO3a nuclear retention via PI3K.\",\n      \"evidence\": \"VLA-4/VCAM-1 overexpression/knockdown with vascular permeability assays and in vivo ascites model; reconstituted supported lipid bilayer with PI3K inhibitors and FOXO3a imaging\",\n      \"pmids\": [\"33295887\", \"34402812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PYK2 is a direct substrate of VCAM-1 outside-in signaling unknown\", \"HSC bilayer findings not yet validated in bone marrow niche in vivo\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"An epigenetic circuit was uncovered: HDAC1/2 sustain VCAM-1 expression by preventing STAT3 acetylation-driven DNMT1 recruitment and GATA6 promoter methylation, linking chromatin remodeling to VCAM-1 transcriptional control in atherosclerosis.\",\n      \"evidence\": \"HDAC1/2 siRNA, romidepsin, STAT3 acetylation-blocking mutant, methylation-specific PCR, ChIP, ApoE⁻/⁻ mouse atherosclerosis model\",\n      \"pmids\": [\"33859766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative importance of GATA4 vs GATA6 in different endothelial beds unresolved\", \"Whether HDAC3 has compensatory roles not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"VCAM-1 on HSCs was revealed as a 'don't-eat-me' signal conferring innate immune tolerance, regulated by β2-microglobulin/MHC-I and recognized by PIR-B on phagocytes; additionally, VCAM-1–bearing endothelial extracellular vesicles were found to mobilize splenic neutrophils after myocardial infarction.\",\n      \"evidence\": \"Conditional Vcam1 KO in haplotype-mismatch transplantation, PIR-B KO phagocytes, phagocytosis assays; CRISPR/Cas9 VCAM-1 deletion in endothelial EV-producing cells with in vivo neutrophil mobilization\",\n      \"pmids\": [\"35210567\", \"35134856\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VCAM-1 don't-eat-me function operates through direct PIR-B binding or via MHC-I co-presentation not distinguished\", \"VCAM-1 EV cargo composition and receptor on splenic neutrophils undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A non-canonical role emerged: IL-33–induced microglial VCAM-1 senses plaque-associated ApoE to direct microglial chemotaxis toward amyloid-β plaques, establishing VCAM-1 as a chemotactic receptor in neurodegeneration.\",\n      \"evidence\": \"VCAM-1–ApoE interaction blocking, Aβ chemotaxis assays, Alzheimer's disease mouse model\",\n      \"pmids\": [\"37735240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"VCAM-1–ApoE binding interface not structurally defined\", \"Whether this represents a direct receptor–ligand interaction or requires co-receptors unknown\", \"Relevance to human AD not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Epigenetic and metabolic regulation of VCAM-1 was extended: H3K18 lactylation activates VCAM-1 transcription in gastric cancer, where VCAM-1 drives AKT–mTOR signaling and CXCL1-mediated immune cell recruitment; NF-κB–dependent tubular VCAM-1 was shown to mediate immune cell adhesion in kidney inflammation.\",\n      \"evidence\": \"H3K18 lactylation ChIP with VCAM-1 overexpression/knockdown and AKT–mTOR inhibitors; TNF-α/IL-1β treatment of tubular cells with NF-κB inhibition and Vcam1 genetic deletion\",\n      \"pmids\": [\"38461905\", \"39116349\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether lactylation-driven VCAM-1 induction is tumor-type specific unknown\", \"Tubular VCAM-1 findings limited to in vitro models\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: how the VCAM-1 cytoplasmic tail couples to NADPH oxidase and β-catenin signaling; the structural basis for dual-integrin (α4β1/α9β1) and ApoE recognition; whether the 'don't-eat-me' function operates through direct PIR-B engagement; and the in vivo functional significance of the distinct 6- and 7-domain isoforms.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoplasmic tail signaling adaptor identity unknown\", \"No high-resolution structure of full-length VCAM-1 with integrin or ApoE\", \"Isoform-specific functions not tested in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 2, 3, 8, 11, 16, 20, 21]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [20, 30, 36]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [18, 30, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 8, 9, 16, 17, 33]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [9, 15, 17, 44]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [44]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 8, 11, 18, 33, 36]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 8, 16, 20, 21, 34]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 18, 25, 30, 34, 42]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 30, 31, 37]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 21, 29, 41, 42]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ITGA4\",\n      \"ITGA9\",\n      \"EZR\",\n      \"MSN\",\n      \"ADAM17\",\n      \"CTNNB1\",\n      \"DLL4\",\n      \"APOE\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}